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ABSTRACT
Vita, Alexandra Adorno. The Role of Berberine, a Clinically Relevant Plant Derived Alkaloid, in
T Cell-Mediated Immunosuppression. Published Doctor of Philosophy dissertation,
University of Northern Colorado, 2021.

The primary focus of this research was to determine the effect of berberine (BBR), a
clinically relevant plant-derived alkaloid, on follicular T helper (Tfh) cell activation and
differentiation, with implications for the generation of T cell-dependent humoral responses. This
research revealed a novel function of BBR as a suppressor of Tfh cell proliferation in secondary
lymphoid organs of BBR-treated mice that underwent immunization for arthritis induction in a
collagen-induced arthritis (CIA) mouse model. Tfh cells provide signaling to B cells that is
crucial for the generation of T cell-dependent humoral responses, such as affinity maturation,
isotype class switching, and the differentiation of germinal center B cells into plasma cells and
memory B cells. While this may be beneficial for patients with antibody-mediated autoimmune
diseases, the results of our preliminary research raise concern that the prolonged use of BBR
could suppress these humoral immunological responses in individuals taking BBR for nonimmune related issues (e.g., management of glucose or lipid metabolism). To address this
concern and support our preliminary observations, we have further delved into the suppressive
impact of BBR on Tfh cell activation and differentiation, as well as the specific mechanisms of
BBR inhibition on these cells. Through these studies we observed that BBR has selective
suppressive effects on signaling pathways downstream of the T cell receptor (TCR) in activated
Tfh cells. Specifically, the phosphorylation of ZAP-70, Lck, and PLCγ1 and the cytoplasmic
store of NFATc1 were unaffected by BBR treatment. However, intracellular Ca2+ mobilization,
iii

STAT3 phosphorylation, and IL-21 production in response to TCR complex stimulus were all
significantly inhibited by BBR treatment. This work reveals previously unknown cellular and
molecular mechanisms of BBR action in the context of immunosuppression. Further research in
the binding partners of BBR, as well as anatomical studies of lymphoid tissue proliferation, will
be necessary to further guide the clinical use of this widely available alternative medicine.
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CHAPTER I
INTRODUCTION
Immunological Background
The immune system can be broken down into two general branches: The innate immune
system, which recognizes general classes of pathogens and is a relatively non-specific first line
of defense, and the adaptive immune system, which recognizes specific antigenic molecular
sequences and can thus generate a highly targeted immune response [1]. While the innate
immune system is composed of many phenotypically and functionally distinct cell types from
multiple cell lineages, the adaptive immune system is predominantly driven by the two main
lymphoid lineage cell types, also known as lymphocytes: B cells and T cells. Although
lymphocytes in general are largely associated with adaptive immunity, it is important to note that
certain T cells (e.g., -T cells) and other lymphoid lineage cells (e.g., Natural Killer cells and
Innate Lymphoid Cells) contribute to innate immune responses [2]. For this dissertation any
further reference to T cells is assumed to mean “conventional” αβ T cells, and B cells shall refer
to B2 B cells since these are the major effectors involved in antigen-specific adaptive responses.
T Lymphocytes (T Cells)
Within the adaptive immune system, there are many developmental stages, distinct cell
phenotypes, and effector functions for both B and T cells. T cells, for example, can be broadly
divided into CD8+ and CD4+ T cells, each named for their characteristic cell surface T cell coreceptor (CD8 or CD4) which they have acquired by the end of their development in the thymus
[3,4]. Each of these T cell fractions widely exist in a naïve, or inactivated and semi-
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undifferentiated state. While both naïve CD8+ and naïve CD4+ T cells must typically be
presented with a foreign, or non-self, antigen in order to become active [4,5], the method of
antigen presentation which activates each highlights the functional difference between these two
classes of T cells.
CD8+ T cells, also called cytotoxic T cells, are largely responsible for identifying infected
self-cells within the body and destroying those cells along with the pathogen that has infected
them (e.g., a virus or intracellular bacterial infection) [3]. For this to occur, the T cell receptor
(TCR), which directly binds antigenic peptides, and CD8 co-receptor on activated CD8+ T cells
interact with a specific cell-surface molecule present on all nucleated cells within the body,
called the Major Histocompatibility Complex (MHC) class I. The MHC class I has the capability
to present antigenic peptide fragments from intracellular proteins on the cell surface and does
this for both intracellular self and foreign (e.g., from a pathogen) proteins. Based in part on
whether the antigenic peptide presented is a self-antigen (i.e., from a self-protein within the cell)
or a foreign antigen (i.e., from an intracellular pathogenic threat), the CD8+ T cell will either take
no further action or begin a process by which it kills the compromised cell and the potential
pathogenic threat inside [3]. To become activated from a naïve state typically requires priming
by a dendritic cell in secondary lymphoid tissue, which will be discussed further in the context of
CD4+ T cells later (the subject T cell family of this dissertation). Once activated, CD8+ T cells
circulate and surveil tissues throughout the body by directly interacting with their cellular targets.
This is particularly important for destroying virally infected cells, as well as cancerous cells
which begin to mutate, change morphologically, and can present irregular antigenic self-peptides
(also known as “neoantigen”) via MHC class I [6,7].
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Rather than targeting infected cells directly, CD4+ T effector cells, also called T helper
(Th) cells, serve to coordinate and amplify the activity of other nearby immune cells, thus
“helping” them respond to an antigenic stimulus. For this to occur, the TCR and CD4 co-receptor
on naïve CD4+ T cells interact with the antigen-presenting MHC class II molecule on a group of
select immune cells formally called professional Antigen Presenting Cells (APCs), which
includes dendritic cells, macrophages, and B cells. This interaction between naïve T cells and
APCs typically occurs within secondary lymphoid organs, such as the spleen or lymph nodes.
The function of MHC class II differs from MHC class I in that it presents antigenic peptide
fragments derived from extracellular self and foreign proteins, which have been engulfed by the
APC from the extracellular environment [3]. By doing this, the APC can inform the CD4+ T cell
of a potential extracellular threat.
Interaction of CD4/TCR with MHC class II, although important, is not sufficient for full
activation of naïve CD4+ T cells. These cells must also receive a strong cell survival signal
through the co-stimulatory receptor CD28, which interacts with CD80/86 on APCs, along with
additional mitogenic and differentiation signals from extracellular soluble factors called
cytokines [3,8]. In this way, activation of naïve CD4+ T cells into fully functional effector Th
cells is a 3-step or 3-signal process: If recognition of foreign antigen (Signal 1) is coupled with
the co-stimulatory CD28 signal (Signal 2), the naïve CD4+ T cells begins to undergo the energy
intensive process of activation, clonal expansion (i.e., make many more copies of itself), and
differentiation in to one of the many CD4+ Th cell effector phenotypes. Th cell effector
phenotypes are functionally distinct CD4+ Th cell subsets that arise when a naïve CD4+ Th cell
becomes activated in the presence of specific cytokines (Signal 3), which are produced by other
nearby cells, especially APCs, in response to the type of pathogen present. The cytokine
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environment is situational, and so the types of cytokines present differ based on type of pathogen
recognized by the APCs and other innate immune effectors, location of immune threat, and
source of production [3,8].
While there are a few emerging CD4+ Th cell effector phenotypes (Th9, Th22), the four
most established and well-described CD4+ Th cell effector phenotypes include Th1, Th2, Th17,
and Tfh cells. Generally speaking, Th1 cells enhance immune responses towards intracellular
pathogens, Th2 cells enhance responses toward extracellular parasites and allergens, Th17 cells
enhance responses toward extracellular pathogens that can be readily phagocytosed, particularly
at mucosal and epithelial barriers, and Tfh cells help generate T cell-dependent humoral
responses [3,8]. Each effector phenotype arises when naïve CD4+ T cells are activated in the
presence of a specific cytokine milieu, thus leading to the activation of lineage specific
transcription factors which drive the differentiation program of a specific effector subset. For
example, activation of the transcription factor Tbet drives the Th1 program, whereas GATA-3
drives Th2 program, RORt drives the Th17 program, and Bcl-6 drives the Tfh program. Each of
these transcription factors are mutually inhibitory, meaning that if one becomes upregulated, it
represses expression of the others. Additionally, each of these CD4+ Th cell effector phenotypes
produce hallmark cytokines which best serve the specific effector function. Th1 cells, for
example, produce large quantities of INF which enhance various CD8+ T cell and macrophage
responses to promote the clearance of cells infected with intracellular pathogens [3,8,9].
Whereas the above descriptions highlight CD4+ Th and CD8+ cytotoxic T effector cells,
which play an active role enhancing immune responses, it is also important to note that within
both CD8+ and CD4+ T cell fractions exists a regulatory cell type called T regulatory cells (Tregs),
though the CD4+ populations within this functional group are much better characterized. Tregs
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serve to shut down or dampen immune responses and play an important role in peripheral
tolerance, the process by which autoreactive and overreactive T effector cells are induced to
become inactive either by clonal deletion, anergy, or conversion into a Treg [10]. Indeed,
disruption in the ratio of Tregs to T effector cells has been implicated in the development and
amelioration of autoimmunity [11]. Tregs can elicit regulatory effects by secreting large amounts
of the immunosuppressive cytokines TGF- and IL-10, along with expressing large quantities of
the cell-surface molecule CTLA-4, which interacts with Th cells through the CD28 costimulatory receptor to provide inactivation signals [10].
B cells and Germinal Center
Responses
Due to T cells’ ability to help target infected cells, as well as amplify the responses of
other immune cells, they are often considered to be the “cellular immunity” branch of the
adaptive immune system. B cells, on the other hand, are known for secreting antibodies into the
extracellular environment, which can then travel through the “humors,” or fluids, of the body to
bind their antigenic target. Because of this, B cells and the antibodies they produce are
considered to be the “humoral” branch of the adaptive immune system.
Within secondary lymphoid organs, B cells that are exposed to foreign antigen can
respond in a T cell-dependent or T cell-independent manner [3], depending on the structure of
the antigen and how robustly it is able to activate the B cell without T cell help. Typically,
antigens that are able to bind to many B cell receptors (BCRs) at once in a process called BCR
cross-linking, or are able to bind BCRs while simultaneously binding nonspecific pathogen
recognition receptors, are able to activate B cells in a T cell independent manner– meaning that
they do not need to interact with T cells in order to activate [3]. Some specific types of B cells,
such as Marginal Zone B cells of the spleen and B1 B cells in the gut, appear to be specialized
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for T-independent activation [12] Antigens that are smaller and might only bind one BCR at a
time, such as proteins, will typically require that B cells receive “help” from, or interaction with,
T cells that recognize the same processed antigen in order to activate. This is the special context
of B cells acting as APCs, wherein they present their specified antigen in a processed form to T
cells via MHC class II. When B and T cells have the capability to recognize the same antigen in
this way, they are called cognate cells, and have the ability to generate an immune response
towards the same exact pathogen (also known as linked recognition) [12]. Activating B cells will
then differentiate into antibody-secreting plasma cells and face a critical cell fate decision based
on whether it is receiving help from cognate CD4+T cells, and in particular cognate CD4+ Tfh
cells.
In short, B cells do not require T cell help to produce antibodies (also known as
immunoglobulins). They do, however, require a stable interaction with cognate Tfh cells to
produce highly specific antibodies that are able to bind their antigenic targets with high affinity
and the full availability of antibody effector functions. There are 5 main classes, or isotypes, of
antibodies: IgD, IgM, IgG, IgA, and IgE. The specific isotype a plasma cell secretes depends on
many factors, including the type of antigenic stimulus, the cytokine environment, and interaction
with T cells [13]. IgM, for example, is a low affinity antibody that is able to be produced by B
cells without T cell help [14,15]. There are also T cell-independant instances where the class, or
isotype, of the antibody can be changed in a process known as class switch recombination, or
class switching. Certain B cells in lymph nodes near mucosal surfaces can class switch from IgM
to IgA without T cell help, although the IgA produced is not a high affinity IgA [15–17].
When an activating B cell maintains stable interaction with its cognate Tfh cell, however,
it has the capability to produce high affinity antibodies via somatic hypermutation. During
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somatic hypermutation, genes encoding the antibody-binding site on the variable region of the
antibody (and the matching BCR, which is essentially a membrane-bound antibody) undergo
rapid genetic mutation as the activating B cells proliferate, resulting in some B cells with higher
affinity antibodies/BCRs than others. As antigen becomes limiting, the antibody-BCR
interactions with the highest affinity will preferentially bind antigen and outcompete those with
lower affinity, causing those with lower affinity to eventually die off after remaining
unstimulated for a period of time [18]. This process only occurs in germinal centers (GCs),
which are transient microanatomical sites in secondary lymphoid organs, specifically within the
B cell follicles, that arise in response to stable Tfh cell-B cell interactions. In immunocompetent
individuals, this interaction occurs in response to the presence of antigen derived from infectious
pathogens, and functions to produce specific high affinity antibodies which will target that
pathogen for destruction or removal. In individuals with antibody-mediated autoimmune
diseases, this interaction can occur erroneously, and lead to an inappropriate antibody response
against self-antigen. Regardless, the somatic hypermutation that gives rise to these high affinity
antibodies is reliant on stable signals from GC Tfh cells in order to occur [19].
T Follicular Helper Cells
T follicular helper cells (Tfh cells) are a specialized subset of CD4+ T helper (Th) cells
that reside within secondary lymphoid organs, and are distinguished from circulating T follicular
helper cells (cTfh cells) by distinct differences in functional and phenotypic characteristics [20–
22]. Tfh cells are typically characterized by the expression of C-X-C Motif Chemokine Receptor
5 (CXCR5), a chemokine receptor that draws Tfh cells toward B cell follicles and, eventually,
into germinal centers [23]. Also expressed is Inducible T Cell Co-Stimulator (ICOS) and
Programmed Death Receptor 1 (PD-1), resulting in a cell population of CD4+ T cells that is
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characteristically CXCR5+ICOS+PD-1+ [23]. These cells play a critical role in the generation of
humoral immunity by aiding in the formation of germinal centers and facilitating T celldependent humoral responses [21,23].
Key Molecules Driving T Follicular
Helper Cell Differentiation and
Effector Function
T follicular helper cell differentiation can be influenced by many factors and is a multistep
process that begins with the priming and activation of naïve CD4+ Th cells upon initial interaction
with and antigen presentation by APCs, such as dendritic cells, in secondary lymphoid tissues. The
commitment of CD4+ Th cells to the Tfh cell lineage versus other Th effector cell phenotypes (e.g.,
Th1, Th2, Th17, etc.) during activation and differentiation is thought to be predominantly driven
early on by the presence of either IL-6 (in mice and humans) or IL-12 (predominantly in humans),
high affinity interaction between the T cell receptor (TCR) and the antigen-presenting MHC class
II on the APC, ICOS signaling, and low levels of the Tfh cell-suppressing cytokine IL-2 [22].
Signaling through the IL-6 receptor and ICOS induces Bcl-6 [22,24], a transcription factor which
commits CD4+ Th cells to the Tfh cell lineage by repressing transcriptional activators of other Th
effector cell phenotypes (e.g., Tbet, RORt, GATA-3). Activation of the Bcl-6 transcription factor
subsequently leads to the expression of CXCR5, a chemokine receptor for CXCL13, as well as an
increased expression of the phenotypically characteristic Tfh cell surface molecules ICOS and
PD-1.
Maturation of pre-Tfh cells into fully functional GC Tfh cells depends on a continued
stable interaction with and antigen presentation by cognate B cells, which pre-Tfh cells can
initially receive upon CXCR5 and ICOS co-mediated migration to the T-B cell border and
eventually into the B cell follicles [22,25]. In the absence of an interaction with cognate B cells,
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pre-Tfh cells will not mature into fully functional GC Tfh cells and the pre-Tfh cell phenotype is
not sufficient to facilitate T cell dependent humoral responses. Tfh cell maturation into a
functional GC Tfh cell is marked by an upregulation of CXCR5, ICOS, and PD-1, all of which act
in concert to keep Tfh cells localized to the germinal center, help ensure that only fully mature
GC Tfh cell with full B cell-helping capacity do so, and promote T cell-dependent germinal
center responses. Whereas CXCR5 and ICOS are both highly involved in migration and
localization of Tfh cells, PD-1 predominantly acts to negatively regulate the expansion of Tfh
cells, and in particular, Tfh cells which lack the high-ICOS expressing phenotype required for
stable interaction with GC B cells and GC localization expansion [22,26,27]. As ICOS signaling
promotes the expression of key Tfh cell molecules that are involved in germinal center activities,
such as CD40L, IL-21 and IL-4 [28,29], as well as the maintenance of the Tfh cell phenotype,
PD-1-mediated selection for ICOS-high expressing Tfh cells (i.e., the Tfh cells with the greatest
effector function capacity) is particularly important for ensuring the development of Tfh that are
reactive to genuine immunological threats.
Regarding Tfh cell molecules that specifically facilitate T cell-dependent humoral
responses in B cells, one of the most significant co-stimulatory signals provided to B cells is the
ligation of CD40L (CD154) on Tfh cells with CD40 on B cells [30]. This interaction is crucial as
it promotes affinity maturation via somatic hypermutation and isotype class switching, as
evidenced by various hyper-IgM syndromes [31,32], the most common of which is X-linked
(type 1) involving a loss of function mutation in CD40L. In these syndromes, loss of CD40L
function renders B cells incapable of generating high affinity antibody responses. The marked
ICOS-mediated upregulation of IL-21 and IL-4 secretion by Tfh cells is also important for
providing proliferation and differentiation signals to nearby B cells [21,22], with IL-21 in
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particular also providing autocrine signals to support the continued expression of key Tfh cellsurface signaling molecules needed for GC localization and effector function[33].
T Follicular Helper Cells
and Disease
As previously mentioned, Tfh cells play a critical role in the generation of humoral
immunity by aiding in germinal center formation, B cell somatic hypermutation and affinity
maturation, isotype class switching, and the differentiation of B cells into long-lived plasma cells
and memory B cells [21]. Due to the requirement of these cells for germinal center responses,
dysregulation in Tfh cell activity can have profound effects on primary immune responses, the
generation of immunological memory, and antibody-mediated autoimmune diseases [5].
The residency of classical Tfh cells within secondary lymphoid organs, however, presents
a significant hurdle to directly studying the roles Tfh cells and germinal center interactions in
specific contexts within human populations, and animal models of disease are the predominant
source of mechanistic data. Within human populations, the role of Tfh cells in health and disease
is largely restricted to characterizing fractions of circulating Tfh (cTfh) cells, high affinity
antibodies produced by activated B cells, and other plasma markers of Tfh cell activity, and then
correlating these with disease incidence and severity [22]. For example, the blood samples from
patients with primary Sjögren’s syndrome and systemic lupus erythematosus, both systemic
antibody-mediated autoimmune diseases, revealed that patients with greater disease severity had
a greater proportion of cTfh cells and IL-21, with the proportion of cTfh cells also correlating with
autoantibody levels [34]. Elevated levels of cTfh cells were also observed in patients with
rheumatoid arthritis and correlated with autoantibody production [35].
Observing GC formation and autoantibody production within ectopic lymphoid structures
(ELSs) provides an additional role for Tfh cells in autoimmunity. ELSs are inducible,
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microanatomical lymphoid sites that are generated ectopic to secondary lymphoid organs at sites
of chronic inflammation. ELSs have been found near sites of chronic inflammation in many
antibody-mediated autoimmune pathologies, such as rheumatoid arthritis, Sjögren’s syndrome,
systemic lupus erythematosus, lupus nephritis, and others [36,37], and evidence shows that ELSs
contain active GC sites that produce autoantibodies [36,38].
While the previous studies highlight the role of Tfh cells in the pathogenesis of disease,
there is also evidence for the importance of Tfh cells in preventing disease, particularly infectious
disease [22]. For example, the virus-specific IgG antibody response towards a vaccinia virus
infection in vivo was reduced by about 57-fold in mice with a defective Tfh cells phenotype [39],
indicating the importance of Tfh cells in GC-derived humoral responses. This importance is
mirrored in vaccine studies, where dysfunctional cTfh cells and an altered IL-21/IL-2 axis were
found in patients with impaired responses to the influenza vaccine [40]. When removed from
patients and examined ex vivo, the cTfh cells of patients with impaired vaccine responses did not
support influenza-specific IgG production by B cells and did not produce IL-21, instead favoring
Th1 and Th17 phenotypes, and IL-2, TNF-, and IL-17 production [40]. In summary, there is
much evidence that Tfh cells play a crucial role in the generation of T cell-dependent antibody
responses.
Complementary and Alternative Medicine (CAM)
As described by the National Institutes of Health (NIH), there exists various methods of
healthcare which fall outside the realm conventional Western medical care. When these
approaches are used in concert with a conventional therapy, they are called “complementary,”
and when used as an alternative option in lieu of a conventional therapy, they are called
“alternative.” CAM encompasses a variety of different practices, including the use of natural
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products such as botanicals and herbal supplements, dietary interventions, mindfulness and
physical activity practices, and more [41].
For certain diseases, complementary and alternative healthcare approaches can have
several benefits, including lower cost and fewer and less severe side effects than standard
pharmaceutical approaches, along with relieving symptoms [42–47]. This is especially so
regarding the currently available treatments for many antibody-mediated autoimmune diseases.
Antibody-mediated autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus
erythematosus, etc.,) occur when the body has an inappropriate immune response and generates
antibodies which target self-tissue. As the pathology is mediated by an active immune system,
treatments are often heavily immunosuppressive. There are several factors (e.g., socioeconomic,
psychosocial, individual health) which may interfere with a patient’s ability or willingness to
adhere to many of the currently available treatment regimens [48–52]. When considering the
standard rheumatoid arthritis treatments, for example, average annual cost can range from around
$2,300-$8,000 for disease modifying antirheumatic drugs (DMARDs) to upwards of $22,000$44,000 for biological immunotherapies [53], although these prices can vary greatly and may
cost some patients upwards of $85,000 per year. Biological immunotherapies, which are the
typically most effective treatments, usually use monoclonal antibodies or receptor/ligand mimics
to target and interrupt specific components of an immune response. Some common treatments
within this class of drugs include adalimumab (a TNF-α neutralizing antibody), etanercept (a
TNF-α receptor competitor), and abatacept (a CTLA-4 competitor), the cost of which can
sometimes average between $30,000-$44,000 per treatment alone [54]. It is important to note
that while some therapies can allow the patient’s disease to reach a state remission, these
therapies do not entirely cure the disease. The list of side effects elicited by these therapies may
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also deter patients from adhering to a treatment regimen, along with the vulnerability to
opportunistic infections incurred by the heavy immunosuppressive nature of these medications
[50,55].
Due to the highly bioactive nature of many plant-derived compounds, as well as having
provided the medical world with many innovative therapies (e.g., paclitaxel, aspirin, opiates,
vinblastine, etc.,) botanicals and herbal supplements represent a reservoir of potential CAM
interventions for antibody-mediated autoimmune pathologies. The National Center for
Complementary and Integrative Health (NCCIH; division of NIH) states that evaluating the
biology and mechanisms behind specific CAM interventions through basic research (e.g., in
vitro, in vivo) is a funding priority [56], further highlighting the importance of investigating
botanicals and their constituents. One such plant-derived compound, berberine, has already proved
to be of clinical importance for a variety of diseases, such as polycystic ovary syndrome, type II
diabetes, and ulcerative colitis. Thus, we will be examining the plant alkaloid berberine and its role
as a potential mediator of T cell-dependent antibody responses.
Berberine
Berberine (BBR) is a plant-derived isoquinoline alkaloid found in the roots, rhizomes and
stem bark of plants within a variety of genera, such as Berberis (its namesake), Mahonia,
Hydrastis, and Coptis, among others. The full breadth of botanical sources, as well as the variety
of extraction methods, are well-described in a recent review by Neag et al (2018) [57]. The use
of in vivo rodent studies has demonstrated that after oral administration, BBR can be found
distributed in tissues such as the liver, brain, heart, kidney, spleen, GI tract and lung [58–62].
The largest accumulation, however, is found in the liver, which is also the primary site of BBR
metabolism. Metabolism is carried out by cytochrome p450 enzymes, with the predominant
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enzymes involved being CYP2D6, CYP1A2, CYP3A4, CYP2E1 and CYP2C19 [62,63].
Following metabolism, there is evidence that certain phase I and phase II metabolites can enter
circulation, accumulate in solid tissues, and have similar pharmacological activities as BBR
[64,65] although to a lesser degree, suggesting that the pharmacological activity attributed to
BBR supplements may in fact be due to both BBR and its metabolites.
Berberine has already proved to be of importance for a variety of diseases through
successful clinical trials, such as polycystic ovary syndrome [66,67], type II diabetes [68,69],
diarrhea-predominant irritable bowel syndrome [70], psoriasis [71], and osteoarthritis [72].
Within each of these trials, the primary pathologies associated with each disease state were
ameliorated through BBR treatment. Additionally, current clinical trials are assessing BBR’s
ability to help ulcerative colitis (UC) patients maintain remission (NCT No.02962245), to
prevent colorectal cancer development in UC patients who are in remission (NCT No.
02365480), and to prevent the recurrence of colorectal adenomas (NCT No. 02226185). Side
effects reported after oral administration are considered to be mild (e.g., diarrhea, flatulence,
abdominal pain, nausea, and constipation), and do not occur in all patients [66,68,69,73]; there
were no adverse effects observed on liver and kidney function [68,69,74]. Notably, amelioration
of the previously mentioned side effects in patients has been reported once dosage was lowered
[69]. Additionally, BBR has been shown to successfully and strongly regulate the inflammatory
responses involved in clinically apparent autoimmune diseases in vivo such as collagen-induced
arthritis [75–78], type I diabetes mellitus [79], UC [80,81], and experimental autoimmune
encephalomyelitis [82].
Currently, BBR is marketed as a dietary botanical supplement by numerous nutraceutical
companies for various functional and general health claims, such as the support of glucose
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metabolism, maintenance of healthy glucose levels, maintenance of healthy cholesterol levels,
gastrointestinal support, cardiovascular health, metabolic support, anti-inflammatory properties,
and to support a healthy immune system.
It has been demonstrated that BBR inhibits the production of a variety of proinflammatory cytokines by various immune cells [83,84], having a strong anti-inflammatory
effect. In regard to CD4+ T cell suppression specifically, BBR has been shown to act in vitro and
in vivo through a number of suggested mechanisms that ultimately inhibit the phosphorylation of
key signaling molecules and/or transcription factors regulating the expression of genes involved
in activation, differentiation, proliferation, effector function of these cells. Berberine-mediated
suppression of JAK/STAT phosphorylation (JAK1, JAK2, STAT1, and STAT4) has been
repeatedly implicated in the inhibition of Th1 differentiation [85–87] and Th17 differentiation
via STAT3 [78,85–87]. One study in particular linked this inhibitory effect on JAK/STAT
signaling to the BBR-induced phosphorylation and activation of AMPK [87]. The suppression of
various MAPK signaling pathways, such as p38 MAPK [86,88], ERK [77,88], and JNK
[77,86,88] have also been observed, where BBR treatment resulted in decreased phosphorylation
of these molecules. Additionally, there is evidence that BBR activates the aryl hydrocarbon
receptor (AhR), which has been linked to the induction of FOXP3 and the T regulatory (Treg)
phenotype from naïve CD4+ T cells [89]. Finally, the activation of AMPK in CD4+ T cells
observed by Takahara et al. (2019) [87] that led to decreased JAK/STAT phosphorylation
indirectly provides a possible mechanism of action for other pathways the can be suppressed by
AMPK activity for which BBR has been shown to inhibit, such as NF-B, MAPK/JNK and
ERK.
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Studies involving the use of BBR with other cell types, such as various monocytic and
non-immunogenic cells, also imply that BBR impacts the activity of NF-B/p65 [90,91],
MAPK/p38/JNK/ERK [88,90], and AhR [92]. Furthermore, there are BBR-mediated suppressive
mechanisms that have been demonstrated only in non-T cell lines, but whose signaling pathways
also exist in CD4+ T cells, such as Akt [88,90], PLCγ1[93] and Ca2+-calcineurin-NFAT
[88,91,93]. Berberine’s effect on these pathways was seen predominantly though impacting the
phosphorylation status of signaling molecules and transcription of gene products, as outlined
extensively in a recent review by Wong et al (2019) [94].
Despite BBR’s observed role in vitro, in vivo, and in select clinical trials as an
immunosuppressant, studies have yet to examine its influence on Tfh cells and subsequent T cell
dependent humoral immune responses. Thus, we will be further examining the
immunosuppressive role of BBR by testing its efficacy in a model of antibody-mediated
autoimmune disease, evaluating its direct effect on Tfh cell differentiation and proliferation, and
the mechanism of action of BBR on Tfh cells.
Significance
Further exploring BBR’s role as an inhibitor of Tfh differentiation, proliferation, and
effector function will provide valuable insight into mechanisms of action that are currently
lacking in the literature. On a cellular level, it will provide a direct mechanism for Tfh
suppression, and on a humoral level, it will provide a mechanism for the suppression of T celldependent antibody responses. This has two important implications. First, this information will
shed light on BBR’s role in collagen-induced arthritis suppression (a murine model of
rheumatoid arthritis) that was observed in our preliminary research as detailed in Chapter II [95].
Second, since these mechanisms are so crucial to adaptive immune function, suppressing these
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functions may have implications for the general safety of BBR as a dietary supplement, and/or its
potential use in antibody-driven autoimmune and hypersensitivity disorders.
Currently, it is unknown exactly how BBR interferes with Tfh cell differentiation and
effector cell function. In our preliminary research using BBR as an immunosuppressive
prophylactic treatment, BBR appeared to reduce IgG autoantibody production and incidence of
arthritis via T cell suppression, including Tfh cell suppression [95]. However, currently a majority
of the cell signaling pathways BBR has been shown to interfere with in T cells (mentioned in
Berberine section above) are pathways that are ubiquitous among various cell types, and so not
necessarily T cell specific. Our proposed pathway of BBR interference with T cell activity, Ca2+calcineurin-NFAT, has not been studied in the context of T cells, let alone Tfh cells. While it is a
pathway that exists in other cell lineages, it plays a critical and irreplaceable role in T cell
activation, especially Tfh cell activation [96]. The importance of this pathway in T cells
specifically is highlighted by the use of cyclosporine, a calcineurin inhibitor, to prevent T cellmediated organ transplant and graft rejection. Additionally, a thorough search of online research
databases leads us to believe that there are no studies to date that specifically examine the
suppressive effect of BBR on CXCR5+ Tfh cells and directly link this effect to a specific
mechanism of action for treating antibody-mediated autoimmunity.
While the Tfh cell-mediated immunosuppression that was observed in our preliminary
research [95] may be beneficial to those who take BBR for antibody-mediated inflammatory
diseases, it may also suppress Tfh cell function in otherwise immunocompetent individuals who
are taking BBR for non-inflammatory pathologies. Such interference with Tfh cell function could
diminish the body’s humoral immune response upon encountering a pathogen, and possibly
make individuals taking BBR more prone to infection. Additionally, this effect could interfere
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with vaccine safety and efficacy. The Centers for Disease Control and Prevention (CDC) [97]
recommends that individuals taking immunosuppressant drugs should not receive live attenuated
vaccines due to safety issues, since real infection and serious adverse side effects may occur.
Although inactivated vaccines are generally considered safe, efficacy becomes the primary issue,
and the degree of immunosuppression a patient may be experiencing due to medication may
render the vaccine less effective. As such, the CDC recommends that individuals should be
vaccinated at least 1 month before starting immunosuppressive therapies. Should BBR suppress
Tfh cell function and humoral immune responses, these recommendations should logically extend
to individuals taking BBR.
However, as BBR is a dietary supplement, it is not regulated in the same way as
pharmaceutical drugs despite it having significant physiological effects and, along with other
dietary supplements, is subject to shockingly minimal oversight by the FDA. While there are
laws and regulations that manufacturers are required to adhere to in accordance with the Dietary
Supplement Health and Education Act of 1994 (DSHEA), they focus predominantly on good
manufacturing practices (GMP) and safety in regards to supplements tainted with toxins or other
harmful material, and only marginally encompass the pharmacologic safety and efficacy of the
marketed ingredient itself [98,99]. Pre-market evaluation of these adherences and approval by
the FDA is not required if the supplement contains ingredients that were on the market prior to
the enactment of the DSHEA, and even new ingredients are frequently placed on the market
prior to approval due to poor regulatory enforcement. The FDA can only intervene regarding a
public safety issue once a product has already been placed on the market, and the burden of proof
is placed on the FDA, not the manufacturer. Moreover, proper oversight and regulation of
evidence-based health claims is lacking, and results in manufacturers being able to base health

19
claims on in vitro cell culture and in vivo animal model studies, without any clinical trial basis
for claims in human physiology. As such, the pharmacologic safety and efficacy of many
botanical dietary supplements are often poorly guaranteed and lacking.
Thus, further investigating the BBR-mediated immunosuppression of CD4+ T cells, and
Tfh cells specifically, would provide valuable insight into a novel function of BBR that would
have important implications for the future testing of BBR in the context of a clinical trial and the
use of BBR as a complementary and/or alternative health intervention.
Specific Aims
Pre-Aim: Assessment of BBR as a prophylactic treatment to delay the onset of collageninduced arthritis. Preliminary research investigating the prophylactic potential of BBR in a
collagen-induced arthritis mouse model (CIA; murine model of rheumatoid arthritis) revealed
that BBR delayed onset of the disease, reduced production of autoantibodies, and appeared to do
so through suppressing CD4+ Th cell activity, including Tfh cells [95]. However, due to the
complex and interconnected nature of a whole-organism disease model, it remains unclear if this
suppression of Tfh cells was due to a direct effect of BBR on these cells, or if BBR was instead
acting upstream of Tfh cell activation and differentiation. Due to the importance of Tfh and B cell
interactions in the generation of thymus-dependent humoral responses, further investigations to
elucidate the specific effects of BBR on Tfh cells became an important next step as the results of
our preliminary research raised concern that the prolonged use of BBR could suppress the
generation of these humoral immunological responses in otherwise healthy individuals. This
effect could potentially interfere with the body’s ability to defend against infection, as well as the
ability to mount effective secondary immune responses via interference with the generation of
humoral immunological memory. Thus, the overarching aim of the subsequent dissertation

20
research is to determine if the use of BBR interferes directly with Tfh cell activation and
differentiation, and if so, how it interferes.
A1

How does BBR impact CD4+T cell CXCR5 expression in a model of humoral
immune response with a BBR intervention?

A2

How does BBR treatment impact Tfh differentiation?

A3

What is the mechanism of BBR effect on Tfh cells?

To address A1, BBR was administered as a prophylactic treatment during induction of
arthritis in a collagen-induced arthritis (CIA) model. CIA is a suitable model to examine Tfh cell
development, as it reliably induces IgG class switching and production of specific anti-collagen
type II (CII) autoantibodies, indicating that Tfh-mediated B cell help is occurring. While we
already observed significantly reduced populations of Tfh cells and anti-CII IgG in the initial data
analysis of our Pre-Aim research [95], we did not examine the expression of key cell surface
molecule CXCR5 on Tfh cells. Thus, we revisited these data to also examine CXCR5 expression
on Tfh cell populations in order to further investigate the method by which BBR led to reduced
disease incidence and anti-CII IgG autoantibody production.
To address A2, Tfh cell populations and expression of Tfh cell markers of lineage and
effector function (CXCR5, ICOS, and PD-1) were measured via flow cytometry following cell
activation and differentiation in the presence or absence of BBR (or a volume-matched vehicle
control). By treating isolated naive CD4+ T cells with BBR during Tfh cell activation and
differentiation we were able elucidate whether BBR has a direct suppressive effect on Tfh cells
versus potentially interfering with immunological processes upstream, such as dendritic cell
activation.
To address A3, we investigated the mechanism of action of BBR’s suppression of Tfh
cells by looking at BBR’s effect on a key signaling pathway involved in T cell activation,
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differentiation, and proliferation following T cell receptor (TCR) ligation: the Ca2+-calcineurinNFAT pathway. Previous studies report that BBR has an inhibitory effect on the Ca2+calcineurin-NFAT signaling pathway in bone marrow derived macrophages (BMMs) and
RAW264.7 macrophages [88,93,100].
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Abstract
There is evidence that berberine (BBR), a clinically relevant plant compound, ameliorates
clinically apparent collagen-induced arthritis (CIA) in vivo. However, to date, there are no
studies involving the use of BBR which explore its prophylactic potential in this model of
rheumatoid arthritis (RA). The aim of this study was to determine if prophylactic BBR use
during the preclinical phase of collagen-induced arthritis would delay arthritic symptom onset,
and to characterize the cellular mechanism underlying such an effect. DBA/1J mice were
injected with an emulsion of bovine type II collagen (CII) and complete Freund’s adjuvant (day
0) and a booster injection of CII in incomplete Freund’s adjuvant (day 18) to induce arthritis.
Mice were then given i.p. injections of 1 mg/kg/day of BBR or PBS (vehicle with 0.01% DMSO)
from days 0 to 28, were left untreated (CIA control), or were in a non-arthritic control group (n =
15 per group). Incidence of arthritis in BBR-treated mice was 50%, compared to 90% in both the
CIA and PBS controls. Populations of B and T cells from the spleens and draining lymph nodes
of mice were examined on day 14 (n = 5 per group) and day 28 (n = 10 per group). BBR-treated
mice had significantly reduced populations of CD4+Th and CD4+CXCR5+ Tfh cells, and an
increased proportion of Foxp3+ Treg at days 14 and 28, as well as reduced expression of costimulatory molecules CD28 and CD154 at both endpoints. The effect seen on T cell populations
and co-stimulatory molecule expression in BBR-treated mice was not mirrored in CD19+ B cells.
Additionally, BBR-treated mice experienced reduced anti-CII IgG2a and anti-CII total IgG
serum concentrations. These results indicate a potential role for BBR as a prophylactic
supplement for RA, and that its effect may be mediated specifically through T cell suppression.
However, the cellular effector involved raises concern for BBR prophylactic use in the context of
vaccine efficacy and other primary adaptive immune responses.
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Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease typically characterized by
chronic inflammation and deterioration within the joints. Extra-articular and systemic
manifestations can also be present depending on the severity of the disease, and some individuals
may experience damage to organs such as the heart, lungs, kidneys, and skin [101]. To date,
there are a number of well-described treatments available for clinically apparent RA. Of these
treatments, conventional disease-modifying antirheumatic drugs (DMARDs) and biological
DMARDs, also known as biologics, are the most effective for long-term management of RA.
However, the effectiveness of these treatments at managing disease progression varies among
patients [101], and can be influenced by genetic factors [102,103] and the duration of symptoms
prior to the first treatment [104–106]. Such interpatient variability in terms of response to
medication can interfere with a patient’s ability to achieve remission and/or the desired level of
disease activity, and can also interfere with a patient’s ability to adhere to a treatment regimen
due to reasons of toxicity, lack of efficacy, and/or high cost [54,107–109].
Due to the large physiological and economic burden this disease places on its patients,
research has become increasingly focused on ways to identify and develop effective preventative
treatments targeting RA during the pre-clinical phase of the disease and thereby delay the onset
of clinical RA [106,110–112]. The pre-clinical phase is commonly defined as the stage of the
disease in which an individual experiences local or systemic autoimmunity, evidenced by
serological abnormalities (e.g., high levels of CRP, TNF-, etc.) and/or autoantibodies (e.g.,
anti-cyclic citrullinated peptide (ACPA), rheumatoid factor (RF), etc.) in the absence of clinical
arthritis [112,113]. Targeting individuals in the pre-clinical phase of the disease with
preventative therapies would provide the earliest initiation of treatment possible and could halt
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disease progression prior to significant joint damage. Furthermore, since the inflammatory load
is far less in patients in the pre-clinical phase than in patients experiencing clinical arthritis, it
presents an opportunity to potentially use lower-cost, broader spectrum complementary therapies
that may be less affected by interpatient variability than conventional DMARDs and biologics,
which act through specific, targeted pathways.
Berberine (BBR) is a plant-derived isoquinoline alkaloid found in the roots, rhizomes,
and stem bark of plants among a variety of genera, such as Berberis (its namesake), Mahonia,
Hydrastis, and Coptis, among others. Berberine merits further exploration as a potential
prophylactic therapy as it has already proved to be of importance for a variety of diseases
through successful clinical trials [66–72]. As such, much is already known about the general
toxicology and common side effects of BBR in humans, which are considered to be mild (e.g.,
diarrhea, flatulence, abdominal pain, and nausea), and do not occur in all patients [15,17,18,22];
there were no adverse effects observed on liver and kidney function [17,18,23]. Notably,
amelioration of side effects in patients was reported once the dosage was lowered [69].
As an anti-inflammatory, BBR successfully suppresses the inflammatory responses
involved in clinically apparent autoimmune diseases in vivo such as collagen-induced arthritis
(CIA; a rodent model of RA) [75–78], type I diabetes mellitus [79], ulcerative colitis (UC)
[80,81], and experimental autoimmune encephalomyelitis (EAE) [82]. In regard to RA
specifically, BBR has been successful at treating clinically apparent CIA and other RA animal
models in vivo through a number of suggested mechanisms, such as (a) dendritic cell apoptosis
[75], (b) interference with MAPK signaling via inhibition of p-ERK, p-38, and p-JNK [77,114],
(c) attenuation of Th17 activity via inducing cortistatin in the gut [78], (d) restoration of the
balance between Treg/Th17 cells [76], (e) the suppression of Th17 differentiation/proliferation
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through inhibition of CD169 and the RORt transcription factor, (f) induction of Treg
differentiation through aryl hydrocarbon receptor (AhR) activation [89], (g) and promotion of
anti-inflammatory M2 macrophage polarization through upregulation of p-AMPK and inhibition
of HIF1a [115]. A more detailed account of the anti-inflammatory actions of BBR in the context
of rheumatoid arthritis can be found in the recent review by Shen et al. (2020) [116].
Despite evidence that BBR ameliorates clinically apparent CIA, to date there are no
studies involving the use of BBR which explore its prophylactic, pre-clinical potential in a CIA
mouse model. Thus, we examined such effects in a CIA mouse model with DBA/1J mice to
determine whether or not BBR merits further exploratory analysis as a prophylactic treatment for
patients in the pre-clinical phase of RA. The main highlights from this study are:
1.

Berberine delays the onset of collagen-induced arthritis in DBA/1J mice.

2.

Berberine treatment reduces splenic and lymph node CXCR5+ follicular T helper
(Tfh) cell populations.

3.

Berberine polarizes splenic and lymph node T cells toward a CD25+ Foxp3+
regulatory (Treg) phenotype.
Materials and Methods

General Reagents
DMSO (VWR, Radnor, PA, USA), isoflurane (VetOne, Boise, ID, USA), bovine type II
collagen in complete Freund’s adjuvant (Hooke Labs, Lawrence, MA, USA), 1X PBS, berberine
hydrochloride (Sigma-Aldrich, St. Louis, MO, USA), ACK lysis buffer (Quality Biological,
Gaithersburg, MD), RPMI 1640 supplemented to 2 M L-glutamine, 1% v/v penicillin/
streptomycin, 1 M sodium pyruvate, 10 M HEPES (all from ThermoFisher, Waltham, MA,
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USA) 0.05 M β-mercaptoethanol (Bio-Rad, Hercules, CA, USA), and 10% fetal bovine serum
(VWR/Seradigm, Radnor, PA, USA).
Berberine Solution
A stock solution of 10 mM berberine dissolved in DMSO was stored at −20 oC when not
in use. For all i.p. injections, this stock solution was diluted in PBS for a final DMSO
concentration of 0.01% and a BBR concentration of 1 mg/kg when delivered to mice.
Antibodies
Brilliant Violet 421 anti-mouse CD4 (clone GK1.5), FITC anti-mouse CD3ε (clone 1452C11), FITC anti-mouse CD19 (clone 1D3/CD19), APC anti-mouse CXCR5 (clone L138D7),
Alexa Fluor 647 anti-mouse Foxp3 (clone MF-14), APC anti-mouse I-A/I-E (clone
M5/114.15.2), PE anti-mouse I-A/I-E (clone M5/114.15.2), PE anti-mouse CD80 (clone 1610A1), APC anti-mouse CD80 (clone 16-10A1), APC anti-mouse CD86 (clone GL-1), PE antimouse CD40 (clone 3/23), PE anti-mouse CD25 (clone 3C7), APC anti-mouse CD154 (clone
MR1), PE anti-mouse CD28 (clone 37.51), and recommended isotype controls (all from
BioLegend, San Diego, CA, USA). For interrogating the Treg population, the manufacturer’s
protocol was followed for intracellular targets.
Mice
DBA/1J mice (6 weeks old) were purchased from Jackson Laboratories (Bar Harbor, ME,
USA). Animals were acclimated to the housing facilities for one week prior to starting
experiments and were housed 3 mice per cage in conditions that were in accordance with
Institutional Animal Care and Use Committee (IACUC) guidelines to minimize distress (IACUC
protocol 1801BD-NP-M-21; Supplemental Figure 2.1). Mice were divided into four groups:
Control (no CIA induction, no treatment), CIA (positive control), PBS (CIA induction, given
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volume-matched vehicle control of PBS with 0.01% DMSO), and BBR (CIA induction, given
BBR treatment, 1 mg/kg per day). Before commencing the full experiment involving cellular
analyses, a pilot study was performed to determine the efficacy of the CIA model (n = 3 per
group). Treatments were administered via i.p. injections 5 times per week (5 days on/2 days off)
and welfare-related assessments were made daily. In the full study (n = 15 per group; 60 animals
total), five mice from each group were euthanized on day 14 (pre-clinical stage), with 10 mice
from each group being euthanized on day 28. All mice were euthanized via CO2 inhalation to
effect in accordance with our approved IACUC protocol.
Collagen-Induced Arthritis Induction
and Assessment
A pre-formulated emulsion of bovine type II collagen and complete Freund’s adjuvant
(Hooke Labs, Lawrence, MA, USA) was injected according to the manufacturer’s instructions
[117]. Briefly, 0.05 mL of the pre-formulated emulsion were injected subcutaneously near the
base of the tail, about 7 to 10 mm distal to the body and at the space in between the ventral and
lateral tail veins. This procedure was repeated with all mice in the CIA, CIA + BBR, and CIA +
PBS groups, and was considered day 0 of the experiment. For mice undergoing full observation
through day 28, on day 18 a booster injection of bovine type II collagen and incomplete Freund’s
adjuvant emulsion was given according to the manufacturer’s instructions [117]. On day 28,
mice were evaluated for the presence of arthritis, and scored on a scale of 0–16 as follows (per
manufacturers’ recommendation [117]): 0 = normal paw, 1 = one or two toes inflamed and
swollen, 2 = more than two toes, but not entire paw inflamed and swollen OR mild swelling of
entire paw without ankle swelling, 3 = entire paw inflamed and swollen (inclusion of ankle
swelling), 4 = severely inflamed and swollen OR ankylosed paw; all paws were assessed for a
total possible score of 16. Arthritis scoring was blinded to the researchers. Examples of mouse
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front and hind paws for each score category can be found in Supplemental Figure 2.2 in
Appendix A.
Enzyme-Linked Immunosorbent
Assay (ELISA)
Blood samples were collected by cardiac puncture immediately following euthanasia of
mice on day 14 and 28. Whole blood samples were then centrifuged to separate plasma from
cellular components. Serum concentrations of anti-collagen type II (anti-CII) total IgG (catalog #
1012T), anti-CII IgG1 (catalog # 20321T), and anti-CII IgG2a (catalog # 20322T) were
measured by ELISA (Chondrex, Redmond, WA, USA) according to the manufacturer’s
instructions [118,119]. Optical densities were taken at 450 nm using a microplate reader.
Flow Cytometry
Single cell suspensions were made from spleens, inguinal lymph nodes (LNs), and
axillary LNs of euthanized mice. Inguinal LNs were chosen in lieu of popliteal LNs because
inguinal LNs are equidistant from the site of injection and the site of hind paw inflammation, and
so are close enough to both sites to reflect the inflammatory responses of both the injection and
the hind paw inflammatory events. To create single cell suspensions, briefly, spleens and LNs
were separately ground, washed with 3 mL of ACK lysis buffer for 5 min, and then strained into
35 mL of complete RPMI 1640. Single cell suspensions were then stained with fluorescent
antibodies specific for cell lineage markers: CD3+CD4+Foxp3− T helper (Th) cells,
CD3+CD4+CXCR5+ T follicular helper (Tfh) cells, CD3+CD4+Foxp3+ T regulatory cells (Treg),
and CD19+ B cells were measured at day 14 and day 28. Spleen and LN cells were also stained
with fluorescent antibodies specific for co-stimulatory molecules involved in T cell and B cell
activation and differentiation: CD154 (CD40L) and CD28 on CD3+CD4+Foxp3− Th cells, CD25
on CD3+CD4+Foxp3+ Treg, and MHC class II, CD40, and CD80/86 on CD19+ B cells. The
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expression of these co-stimulatory molecules was measured by calculating the geometric mean
fluorescence intensity (MFI) at day 14 and day 28. CD3+CD4+ staining was used as the parent
gate for all the T cell subsets observed in this study. Example gating strategies can be found in
Supplemental Figures 2.3 and 2.4 in Appendix A.
Statistical Analysis
The assumption of normality was not met for cell population data but was met for costimulatory molecule expression data. A chi-square (Χ2) test was used to compare absolute
arthritic incidence (score ≥ 2) among control and treatment groups. For comparisons of nonnormally distributed cell populations, the Kruskal–Wallis test with Dunn’s multiple comparisons
or Mann–Whitney U test were used. For comparisons of normally distributed co-stimulatory
molecule expression data, the ANOVA test with Tukey’s multiple comparisons test was used.
All tests had an  = 0.05. All analyses were performed using Prism version 8 (GraphPad, San
Diego, CA, USA).
Results
Berberine Treatment Delays Onset
of Collagen-Induced Arthritis
To assess BBR’s ability to delay the onset of clinical CIA, mice were observed daily for
signs of redness and joint swelling as an indication of arthritis development, and severity of
arthritis was scored on a scale of 0–16 as previously described. When mice were euthanized on
day 28, we observed a significant reduction in absolute incidence of arthritis in the BBR group
compared to the CIA and PBS controls (see Figure 2.1A). About 90% of mice in both the CIA
and PBS control groups developed arthritis, compared to 50% in the BBR group. In mice who
developed arthritis, however, there was a trend but no significant difference in severity (see
Figure 2.1B).
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Figure 2.1. Assessment of collagen-induced arthritis (CIA) in DBA/1J mice in the context of
berberine (BBR) treatment. (A) Absolute incidence of arthritis (proportions of animals with score
≥2) among treatment groups at day 28 compared using Χ2 (n = 10 per group, * p < 0.05). Incidence
proportions were BBR = 50%, CIA = 90%, PBS = 90%, and CONT = 0%. (B) Arthritis score, on
a scale of 0-16 per manufacturer’s protocol (as described in Materials and Methods), of mice at
day 28 treated with BBR (1 mg/kg/day), volume-matched 1X PBS with 0.01% DMSO (PBS
vehicle control), or no treatment (CIA control). Multiple comparisons conducted using the
Kruskal–Wallis test with Dunn’s multiple comparisons (n = 10 per group).
The Effect of Berberine on Circulating
Anti-CII IgG in the Collagen-Induced
Arthritis Mouse Model
To determine if BBR prophylactic treatment reduces autoantibody production, serum
concentrations of anti-CII total IgG, anti-CII IgG1, and anti-CII IgG2a autoantibodies were
measured at the day 28 endpoint. The BBR group saw significantly reduced serum
concentrations of anti-CII IgG2a and anti-CII total compared to both CIA and PBS controls,
although there was no significant difference in anti-CII IgG1 in BBR mice compared to CIA
control mice (see Figure 2.2A). To further examine if the aforementioned results were an artifact
of including both arthritic and non-arthritic mice in the dataset, comparisons of just arthritic mice
were performed. In this comparison, levels of anti-CII IgG2a among arthritic mice in the BBR
group remained significantly reduced compared to CIA and PBS controls (see Figure 2.2B).
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When comparing anti-CII IgG levels between arthritic and non-arthritic mice within the BBR
group specifically, anti-CI IgG1, IgG2a, and total IgG were all significantly reduced in the nonarthritic mice compared to those who developed arthritis (see Figure 2C). Additionally, there
appeared to be a vehicle-specific effect on circulating anti-CII IgG in which the administration of
PBS with 0.01% DMSO elicited elevated levels of anti-CII IgG1 and total IgG in vehicle control
mice (see Figures 2.2A and 2.2B).
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Figure 2.2. The effect of berberine on circulating anti-bovine type II collagen (CII) IgG in the
collagen-induced arthritis model. (A) Anti-CII IgG1, IgG2a, and total IgG at day 28 among all
mice (arthritic and non-arthritic) within BBR, PBS (vehicle control), CIA (no treatment control),
and non-CIA control animals (n = 10 per group). (B) Anti-CII IgG levels at day 28 compared
among arthritic mice only (BBR n = 5; PBS n = 9; CIA n = 9). Statistical comparisons made with
the Kruskal–Wallis test with Dunn’s multiple comparisons. (C) Anti-CII IgG levels at day 28
compared among BBR-treated mice who developed arthritis (“arthritic”) vs. those that did not
(“non-arthritic”). Statistical comparisons made with the Mann–Whitney U test. For all statistical
tests in Figures 2.2 A–C, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
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Key CD4+T Cell Population and Co-Stimulatory
Molecule Characteristics in Response to
Berberine Treatment
On day 14, we observed a significant reduction in populations of both CD4+T cells and
CXCR5+Tfh cells in the LNs and spleen of BBR-treated mice (se Figures 2.3A and 2.3B), as well
as a reduction in the expression of CD28 and CD154 on CD4+T cells in the spleen and LNs of
BBR-treated mice (see Figures 2.4A and 2.4B). By the day 28 experimental endpoint, we
continued to observe a significant reduction in CD4+T cells and CXCR5+Tfh cells in the spleen
and LNs of BBR-treated mice (see Figures 2.3C and 2.3D), as well as decreased expression of
CD28 and CD154 on the CD4+T cells of BBR-treated mice (see Figures 2.4C and 2.4D).

Figure 2.3. CD4+ T cell populations during pre-clinical collagen-induced arthritis (day 14) and
at final day 28 endpoints. Cells compared were from the CD4+ T cell population of lymph nodes
(LNs) and spleen with further investigation into CD4+ T cell populations expressing specific
cell-surface markers. Shown are populations of CD4+ Th and CXCR5+ Tfh cells of the LN (A)
and spleen (B) at the day 14 endpoint (n = 5 per group), and of the LN (C) and spleen (D) at the
day 28 experimental endpoint (n = 10 per group). Statistical comparisons made with the
Kruskal–Wallis test with Dunn’s multiple comparisons (* p < 0.05 and ** p < 0.01).
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Figure 2.4. Expression of co-stimulatory molecules on CD4+ T cells during pre-clinical CD4+ T
cell populations during pre-clinical collagen-induced arthritis (day 14) and at final day 28
endpoints (day 14) and at final day 28 endpoints. Cells compared were from the CD4+ T cell
population of LN and spleen with further investigation into the expression of co-stimulatory
molecules CD28 and CD154 on CD4+ T cell populations. Shown are expression of CD28 and
CD154 on CD4+ T cells of the LN (A) and spleen (B) at the day 14 endpoint (n = 5 per group),
and of the LN (C) and spleen (D) at the day 28 experimental endpoint (n = 10 per group).
Statistical analysis of co-stimulatory molecule expression made with ANOVA and Tukey’s
multiple comparisons tests (* p < 0.05; ** p < 0.01, *** p < 0.001).
Berberine Treatment Leads to Increased
Proportion of Foxp3+CD4+CD25+
T Cells
To examine BBR’s effect on Treg populations, cells from the CD4+ CD25+ T population
of LN or spleen were measured for the presence of the definitive Treg transcription factor Foxp3.
Out of this subset of cells, we observed an increased ratio of Foxp3+:Foxp3− cells in the spleen
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and LNs of BBR-treated mice during the pre-clinical phase of CIA (day 14 endpoint; see Figure
2.5A). At the day 28 endpoint, BBR-treated mice had a significantly increased ratio of
Foxp3+:Foxp3− cells in the LNs, but not the spleen (see Figure 2.5B). In order to determine
whether or not the previously mentioned results were an artifact of including both arthritic and
non-arthritic mice in the analysis, we compared this ratio between mice in the BBR group who
developed arthritis and the mice who did not. There was no significant difference in the day 28
splenic Foxp3+:Foxp3− T cell ratio between arthritic and non-arthritic mice in the BBR group.
However, all non-arthritic BBR-treated mice had a larger percentage of Foxp3+ cells compared
to Foxp3- cells (ratio of >1) except for one outlier, whereas all arthritic BBR-treated mice had a
smaller percentage of Foxp3+ cells compared to Foxp3- cells (ratio of <1) (see Figure 2.5C).
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Figure 2.5. Berberine induces Treg expansion in lymphoid tissue during collagen-induced
arthritis induction. Cells compared were from the CD4+ CD25+ Th population of LN or spleen
with further interrogation of the definitive Treg transcription factor Foxp3. (A) The
Foxp3+:Foxp3− ratio during the pre-clinical phase of arthritis (day 14) (n = 5 per group, * p <
0.05). (B) The Foxp3+: Foxp3− ratio at the day 28 experimental endpoint (n = 10 per group, * p <
0.05 and ** p < 0.01). (C) Comparisons of Foxp3+: Foxp3− ratios from LN and spleen of the
BBR treated group separated by status as arthritic or non-arthritic. Ratios compared using the
Kruskal–Wallis test with Dunn’s multiple comparisons. Arrow denotes outlier.
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Key CD19+ B Cell Population and Co-Stimulatory
Molecule Characteristics in Response
to Berberine Treatment
Although there was a trend of reduced CD19+ B cell populations in the spleen and LNs of
BBR-treated mice during CIA development (day 14), this trend was non-significant.
Additionally, BBR treatment did not reduce expression of the co-stimulatory molecules MHC II,
CD40, and CD80/86 on CD19+ B cells of the spleen and LNs at day 14 (see Figures 2.6A and
2.6B). By day 28, we observed a significant reduction in CD19+B cells in the LNs, but not
spleen, of BBR-treated mice (see Figures 2.6C and 2.6D). While there was a trend of reduced
expression of the co-stimulatory molecules MHC II, CD40, and CD80/86 on CD19+ B cells in
the spleen and LNs of BBR-treated mice at day 28, this trend was non-significant (see Figures
2.6C and 2.6D).
We did, however, observe a vehicle-specific effect similar to that seen in the anti-CII IgG
data. There were significantly larger CD19+ B cell populations in both the spleen and LNs of the
PBS control mice compared to the BBR-treated mice, and non-significant trends of increased costimulatory molecule expression (see Figures 2.6A-D).
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Figure 2.6. CD19+ B cell populations and expression of co-stimulatory molecules during preclinical collagen-induced arthritis (day 14) and at final day 28 endpoints. Cells compared were
from the CD19+ B cell population of LN and spleen with further investigation into CD19+ cell
populations expressing specific cell-surface markers. Shown are populations of CD19+ B cells and
expression of co-stimulatory molecules MHC Class II, CD40, CD80, and CD86 on CD19+ B cells
in the LN (A) and spleen (B) at the day 14 endpoint (n = 5), and of the LN (C) and spleen (D) at
the day 28 experimental endpoint (n = 10). Statistical analysis of CD19+ B cell populations made
with the Kruskal–Wallis test with Dunn’s multiple comparisons (* p < 0.05), and statistical
analysis of co-stimulatory molecule expression made with ANOVA and Tukey’s multiple
comparisons tests (* p < 0.05 and ** p < 0.01).
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Discussion
Our results indicate that BBR treatment during the pre-clinical phase of CIA delayed the
onset of CIA in DBA/1J mice, although mice in the BBR group who developed arthritis did not
experience a significant decrease in clinical arthritis score compared to the CIA and PBS
controls. Our results provide evidence at the cellular level that the mechanism underlying this
protective effect is directly mediated through effector CD4+ Th cell suppression, which
subsequently influences activation, proliferation, and autoantibody production by B cells.
Our hypothesis that BBR is exerting its effect via CD4+ Th cell suppression is supported
by the observations that BBR-treated mice had significantly reduced populations of CD4+ T cells
and reduced expression of co-stimulatory molecules—effects which were not mirrored in CD19+
B cells. While our CD4+ T cell population data included all T cell subsets expressing CD4 (both
Th and Treg), we observed a higher ratio of Foxp3+CD25+CD4+ T cells (representative of Treg) to
Foxp3- cells within the spleens and LNs of BBR-treated mice. This indicates that although the
overall population of CD4+ T cells was smaller in BBR-treated mice, they also had a higher
proportion of Treg within the total CD4+ T cell population. Additionally, a specific subset of the
overall CD4+ T cell population which plays a key role in T cell-dependent humoral responses,
CD4+CXCR5+ Tfh cells, was also decreased in BBR-treated mice. Together, these observations
indicate a preference toward an immunosuppressive environment and specifically a reduced
capacity to provide help in activating B cell autoantibody production.
A previous study by Moschovakis et al. (2017) [120] examining the role of CXCR5+ Tfh
cells in RA showed that T cell-specific CXCR5 deficiency prevented RA development.
Furthermore, an in vivo CIA study involving the use of hydroxychloroquine (HCQ) as a
prophylactic (administered from day 0 of the experiment) noted a reduction in Tfh cells, which
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corresponded to a decrease in both incidence and arthritis score in HCQ-treated mice [121].
Similar to this evidence, it is possible that our observation of reduced populations of CXCR5+Tfh
cells seen in the BBR group compared to the CIA and PBS controls contributed to a lower
incidence of arthritis as well. The reduction of CXCR5+Tfh cells we observed also likely
contributed to the decreased generation of anti-CII total IgG and subtypes, as CXCR5+Tfh cells
play a critical role in germinal center formation, B cell affinity maturation, isotype class
switching, and subsequent autoantibody production [21]. As such, we propose the mediation of
CXCR5+Tfh cell proliferation as a novel function of BBR, and we are unaware of any studies to
date that specifically address the effect of BBR on CXCR5+Tfh cell populations.
Additionally, the reduced expression of co-stimulatory molecules CD28 and CD154
during CIA development (day 14) and at the day 28 endpoint in BBR-treated mice could be
indicative of reduced activation and proliferation of CD4+ T cells, thereby resulting in the lower
CD4+ T cell populations observed in the BBR-treated group. The blockade to CD4+ T cell costimulation has proven to be an effective RA treatment and is the mechanism of action of
abatacept, a biological immunotherapy used to treat clinically apparent RA [101,122]. CD28CD80/86 interaction is an important therapeutic target as CD28 ligation leads not only to
increased T cell proliferation and activation, but also to increased CD154 expression [123];
CD154 is a crucial ligand involved in the activation of B cells and other APCs, as well as affinity
maturation and isotype class switching in B cells. We would also like to highlight that the
reduced T cell populations and expression of co-stimulatory molecules was seen throughout the
entirety of the experiment (day 14 and day 28). However, since BBR treatment occurred for the
duration of the experiment, it is unknown whether the sustained reduction observed is due to the
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continual administration of BBR, or if ceasing BBR administration would have altered this
outcome.
Berberine’s protective effect against CIA development is also likely mediated through its
alteration of the Foxp3+: Foxp3− CD4+ T cell ratio. With the exception of the day 28 splenocytes
whose data were skewed by one outlier, the BBR group saw a significantly higher proportion of
Foxp3+CD25+CD4+ T cells (Treg) compared to CIA and PBS controls. Thus, while BBR
treatment resulted in lower overall CD4+ T cell populations, a higher percentage of cells within
that reduced population were Treg. Previous studies corroborate the protective effect of Treg on
CIA development; adoptive transfer of CD25+ Treg slowed disease progression of clinically
apparent CIA [124], and the depletion of CD25+ Treg prior to immunization with bovine type II
collagen (used to induce CIA) exacerbated arthritis [125]. Additionally, prior studies using BBR
to ameliorate clinically apparent CIA resulted in a suppression of Th17 activity alongside the
activation/proliferation of Treg, thereby resulting in an increased Treg/Th17 ratio in BBR-treated
mice [76,89]. While a study by Yue et al. (2017) [78] provides opposing evidence in which BBR
did not appear to have a significant effect on the frequency of Treg in a CIA model despite seeing
amelioration of clinically apparent CIA, their particular model used peripheral blood
mononuclear cells to assess the Treg population and Foxp3 expression, as opposed to our study
which observed splenocytes and draining LN cells at the site of immune activation.
In regard to B cell-specific responses to BBR, during CIA development (day 14 endpoint)
the BBR-treated mice in our study did not see a significant reduction in overall CD19+ B cell
populations or expression of co-stimulatory molecules compared to the CIA control. However,
by day 28 we observed a significant reduction in CD19+ B cell populations in the draining LNs
of BBR-treated mice compared to the CIA control, as well as a reduction in anti-CII IgG2a and
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total IgG. As such, we propose that the reduction in day 28 LN B cell populations and the
subsequent lowering of anti-CII autoantibody production are largely due to BBR interfering with
the T cell-mediated activation of B cells via T cell suppression, thereby contributing to decreased
B cell activation. This interference could be due not only to the decreased CD4+CXCR5+ Tfh cell
populations and enhanced proportion of Treg seen throughout the experiment in BBR-treated
mice, but also the decrease in the expression of CD28 and CD154 on T cells seen throughout the
experiment. Both CD28–CD80/86 and CD154–CD40 interactions play an important role in B
cell activation and proliferation, and CD154–CD40 ligation specifically provides key signaling
for thymus-dependent humoral immunity responses, such as the isotype class-switching and
affinity maturation required to generate high-affinity anti-CII IgG autoantibodies [126–128].
Furthermore, previous research has demonstrated that the disruption of CD28–CD80/86 and
CD154–CD40 interactions results in reduced anti-CII autoantibody titers, prevention of disease
development, and/or amelioration of disease in CIA and other autoimmune arthritis models
[129–133]. In other words, pro-inflammatory T cell development and activation is inhibited by
BBR early, which leads to a later reduction in B cells reactive to CII stimulus, and this timing fits
with classical T cell-mediated B cell activity.
While there was no significant difference in anti-CII IgG1 observed between the BBR
group and CIA control, we did observe a significant reduction in anti-CII IgG2a. Moreover,
BBR-treated mice who experienced a delay in onset (remained non-arthritic by day 28, despite
CIA induction) had significantly lower concentrations of anti-CII IgG1, anti-CII IgG2a, and antiCII total IgG compared to BBR-treated mice who developed arthritis. In CIA, the IgG subtype
that is thought to play the most direct role in inflammation and joint destruction is anti-CII
IgG2a, which predominantly activates the complement cascade, although it can also bind
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Fc receptors (FcR) on FcR-bearing immune cells. High concentrations of anti-CII IgG1 are
also typically present, however, IgG1 more readily binds to and activates FcR-bearing immune
cells and has a lower affinity for activating complement compared to IgG2a [134,135]. The
important role of complement activation in CIA pathology is supported by studies that
demonstrated amelioration of CIA in response to complement deficiency [136] and that C5deficient mice were resistant to CIA development [137]. As IgG2a is a strong activator of
complement in mice, IgG2a serum concentration has been shown to correlate to the degree of
inflammation as well as cartilage and bone destruction in CIA models [138], and reduced serum
concentrations of IgG2a were associated with delayed onset and reduced frequency of arthritis
incidence [139,140]. However, a notable difference with our study is that while we observed
significantly lower concentrations of IgG2a in BBR-treated mice compared to CIA and PBS
controls, we did not see any significant difference in the degree of observable inflammation
(arthritis scores). Additionally, as previous studies involving the use of BBR to treat clinically
apparent CIA reported a significant reduction in anti-CII IgG1 in BBR-treated mice compared to
both CIA and PBS controls [75,77], the lack of significant anti-CII IgG1 reduction in the BBR
group compared to the CIA control in our own study was unexpected. It is notable, however, that
when comparing arthritic and non-arthritic mice within the BBR group alone, the non-arthritic
mice had significantly lower concentrations of both anti-CII IgG2a and anti-CII IgG1, indicating
that the observed reduced incidence of arthritis is likely in part due to a reduction in circulating
autoantibodies, as seen in other studies [139,140].
One major unexpected result regarding anti-CII autoantibody production involved a
vehicle-specific effect in which the PBS control group saw the highest increase in autoantibody
production in comparison to the CIA control and BBR group. Our solution of BBR dissolved in
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PBS and 0.01% DMSO was modeled in part after a previous CIA study that used BBR dissolved
in a PBS/DMSO solution containing a slightly greater concentration DMSO than our own [77];
this previous study did not report elevated levels of anti-CII total IgG or anti-CII IgG subtypes in
PBS control groups. However, DMSO has demonstrated the ability to stimulate antibody
production in hybridoma cells, which are myeloma-B cell hybrids commonly used to generate
large quantities of monoclonal antibodies in research and industry settings [141]. In light of this,
it is possible we witnessed a B cell-specific response to the presence of DMSO, and furthermore
that treatment of BBR was able to overcome this effect.
In addition to this unexpected vehicle-specific effect, our model also faced limitations.
One major limitation was the final day 28 endpoint; prolonging the final endpoint past day 28
would provide more insight into the preventative capabilities of BBR. Due to the fact that our
non-arthritic mice continued to have suppressed populations of CD4+ T helper cells and CXCR5+
Tfh cells, higher relative percentages of Treg, and lower concentrations of circulating
autoantibodies by day 28, we hypothesize that it is likely BBR treatment would at least continue
to delay CIA development to a certain point. However, it is not known whether BBR would
entirely prevent CIA development in those mice who remained non-arthritic by day 28, or if they
would eventually develop symptoms of clinical arthritis at a later timepoint. Additionally, having
equal sample sizes between the day 14 and day 28 endpoints would have allowed us to evaluate
the progression of the immune response statistically, as opposed to just speculatively.
This model is further limited in that it assumes a mouse would be able to absorb the i.p.
administered dose via oral administration, which is the preferred route of administration for
human patients taking BBR dietary supplements. While estimates vary, it is widely known that
BBR has an extremely low oral bioavailability (<1%) [59,142,143]. Thus, this model is not
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entirely reflective of how a human patient would ideally receive BBR as a treatment, nor of how
a patient would absorb and distribute BBR as an orally delivered treatment. Finally, this model
would have further benefited from a BBR control group, which would have involved receiving a
BBR treatment but no CIA induction. This would have allowed us to examine the effects of BBR
on the immune system under normal physiological conditions and could have provided us with
additional insights into BBR’s immunosuppressive capabilities.
Concluding Remarks
In conclusion, BBR likely has protective effects against CIA development by directly
suppressing CD4+ T helper cell activity, including CXCR5+ Tfh cells, thus having an indirect
effect on B cell activation and autoantibody production. These T cell suppressive effects are
evidenced by reduced expression of co-stimulatory molecules on CD4+ T cells during CIA
development (day 14) and at the final day 28 endpoint, as well as smaller populations of CD4+ T
cells (including CXCR5+ Tfh cells), and higher percentages of Treg in BBR-treated mice
throughout the experiment. Although populations of CD19+ B cells were reduced in the draining
lymph nodes of BBR-treated mice by day 28, these suppressive effects are not reflected in other
B cell populations throughout the experiment or the expression of co-stimulatory molecules on
CD19+ B cells of the spleen and LNs, indicating that reduced anti-CII auto-antibody production
is likely due to decreased interaction of B cells with activated CXCR5+ Tfh cells. In the future, it
is important to repeat this experiment with a later endpoint to better determine the duration of
BBR’s protective effects. Additionally, it is imperative to more closely examine BBR’s influence
on CXCR5+ Tfh cells, as these cells are crucial to the formation of germinal centers, high-affinity
class-switched plasma cells, memory B cells, and the humoral immunological memory that is
ultimately borne out of germinal center reactions. As such, BBR’s suppressive effect on
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CXCR5+ Tfh cell populations, while potentially beneficial for autoimmune pathologies, also
raises concern that prolonged use could impact a patient’s ability to mount effective beneficial
primary adaptive immune responses.
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Abstract
Our previous research revealed a novel function of berberine (BBR), a clinically relevant
plant-derived alkaloid, as a suppressor of follicular T helper (Tfh) cell proliferation in secondary
lymphoid organs of BBR-treated mice that underwent immunization for arthritis induction in a
collagen-induced arthritis (CIA) mouse model, a common murine model for rheumatoid arthritis.
The interaction between Tfh cells and B cells is crucial for thymus-dependent humoral responses,
and so while the previously observed suppression of Tfh cells by BBR may be beneficial for the
mitigation of antibody-mediated autoimmune diseases, it also raises concern that the prolonged
use of BBR could suppress the generation such responses during infection or vaccine-induced
response. In our current research we explored the direct effects of BBR in vitro on the
proliferation and differentiation of Tfh cells from isolated naïve CD4+ T cells (>95% pure) by
examining cell populations and the expression of the key Tfh cell surface molecules CXCR5,
ICOS, and PD-1. Such molecules are crucial for Tfh cell localization to B cell follicles and
effector function. The treatment of BBR at 0.25 M/mL, 0.50 M/L, and 1 M/mL
significantly reduced the expression of both CXCR5 (p-values <0.01) and ICOS (p-values <
0.005), but not PD1, and reduced the percentage of Tfh cells within the total CD4+ T cell
population. It is important to note that in preliminary concentration-response experiments, 0.50
M/mL was the highest dose of BBR that did not significantly lead to cell death, indicating that
the decreased expression of CXCR5 and ICOS on 0.25 M/ml and 0.50 M/ml are likely not due
to cytotoxic effects. In the future, we plan to elucidate the mechanism by which BBR inhibits the
expression of CXCR5 and ICOS by examining key cell signaling pathways that lead to Tfh
activation and differentiation, and ultimately to CXCR5 and ICOS expression, following BBR
treatment.
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Introduction
Our previous research investigating the prophylactic potential of BBR in a collagen
induced arthritis mouse model (CIA; murine model of rheumatoid arthritis) revealed that BBR
delayed onset of the disease, reduced production of autoantibodies, and appeared to do so
through suppressing CD4+ T helper cell activity, including a novel function of suppressing the
proliferation of T follicular helper (Tfh) cells specifically [95]. Owing to the complex and
interconnected nature of a whole-organism disease model, however, it was undetermined if the
observed suppression of Tfh cells was due to a direct effect of BBR on these cells or if BBR was
instead acting upstream of Tfh cell activation and differentiation, such as interfering with the
activity of antigen presenting cells. Due to the importance of Tfh cell and B cell interactions in
the generation of T cell-dependent humoral responses, further investigations to elucidate the
specific effects of BBR on Tfh cells became an important next step.
T Follicular Helper Cells
T follicular helper cells (Tfh cells) are a specialized subset of CD4+ T helper (T) cells that
reside within secondary lymphoid organs and are typically characterized as CXCR5+ICOS+PD1+ cells within the CD3+CD4+ T cell population [20–22]. These cells play a critical role in the
generation of humoral immunity by aiding in germinal center formation, B cell affinity
maturation, isotype class switching, and the differentiation of B cells into long-lived plasma cells
and memory B cells [21]. Under normal physiological conditions, this is particularly important
for generating specific, high affinity antibodies during primary immune responses that take place
due to infection and/or vaccination, as well as for generating long-term humoral immunological
memory. This antigen-specific interaction between B cells and Tfh cells during primary immune
responses allows for more rapid and robust secondary immune responses upon re-exposure [5].
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Tfh cells’ effector function of facilitating high-affinity antibody production can also be
pathogenic, however. When exacerbated, this can be a driving force in some antibody-mediated
autoimmune pathologies and graft rejection, and when suppressed, can diminish the body’s
ability to safely and effectively respond to pathogens and/or vaccines.
Key Molecules Driving T Follicular
Helper Cell Differentiation and
Effector Function
The commitment of CD4+ Th cells to the Tfh cell lineage versus other Th effector cell
phenotypes (e.g., Th1, Th2, Th17, etc.) during activation and differentiation is thought to be
predominantly driven early on by the presence of either IL-6 (in mice) or IL-6/IL-12 (in
humans), high affinity interaction between the T cell receptor (TCR) and the MHC class II on the
APC, ICOS signaling, and low levels of the Tfh cell-suppressing cytokine IL-2 [22]. Signaling
through the IL-6 receptor and ICOS induces Bcl-6 [22,24], a transcription factor which commits
CD4+ Th cells to the Tfh cell lineage by repressing transcriptional activators of other Th effector
cell phenotypes (e.g., Tbet, RORt, GATA-3). It has been hypothesized that the prolonged
contact between CD4+ Th cells and APCs afforded by a high affinity TCR:MHC class II
interaction potentially increases the length of time that the ICOS receptor on CD4+ Th cells is
able to interact with its ligand, ICOS-L, found on nearby APCs, thus further driving the
expression of Bcl-6 and the initial commitment to Tfh cell program [144]. Activation of the Bcl-6
transcription factor subsequently leads to the expression of CXCR5, a chemokine receptor for
CXCL13, as well as an increased expression of the phenotypically characteristic Tfh cell surface
molecules ICOS and PD-1. These cell surface molecules, however, are not yet expressed in high
quantities on these newly differentiated “pre-Tfh” or transitional Tfh cells, a fact which is
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important to note as it distinguishes the pre-Tfh cell phenotype from fully mature germinal center
(GC) Tfh cells which have a higher expression of each [22].
Maturation of pre-Tfh cells into fully functional GC Tfh cells depends on a continued
stable interaction with and antigen presentation by cognate B cells, which pre-Tfh cells can
initially receive upon CXCR5 and ICOS co-mediated migration to the T-B cell border and
eventually into the B cell follicles [22,25]. While CXCR5 predominantly contributes to the
directionality of Tfh cell migration by sensing and following the concentration gradient of its
ligand CXCL13, which is abundant in B cell follicles, ICOS appears to predominantly contribute
to the motility of Tfh cells via PI3K-mediated actin rearrangement and pseudopod activity [145].
In regard to ICOS signaling in Tfh cells specifically, there is evidence for the importance of
bystander B cells in providing these continued signals which not only facilitate Tfh cell migration
to the T-B border, but also ultimately help maintain the Tfh cell phenotype and germinal center
effector functions [145].
It is important to note that in the absence of an interaction with cognate B cells, pre-Tfh
cells will not mature into fully functional GC Tfh cells and the pre-Tfh cell phenotype is not
sufficient to facilitate T cell dependent humoral responses. Tfh cell maturation into a functional
GC Tfh cell is marked by an upregulation of key co-stimulatory, chemotactic, and other signaling
molecules that are crucial to keeping only those cells which possess the distinct phenotype of the
GC Tfh cell localized to the germinal center (i.e., not only making sure that GC Tfh cells stay
localized to germinal centers, but also that only fully mature GC Tfh cells which have full B cellhelping capacity stay localized to germinal centers), and (2) Tfh cells effector function of
promoting germinal center formation and T cell-dependent humoral responses, such as B cell
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affinity maturation, isotype class switching, and the differentiation of B cells into plasma cells
and memory B cells.
In regard to molecules that keep Tfh cells localized to the germinal center and ensuring
that only phenotypically distinct GC Tfh cells do so (as opposed to cells with only a pre-Tfh cell
phenotype), the dynamic interaction between CXCR5, ICOS, and PD-1 plays a crucial role.
CXCR5 and ICOS both become expressed in higher quantities the longer that Tfh cells interact
with cognate B cells, and further contributes to the migration and localization of Tfh cells into the
B cell follicle and germinal center [22]. Aside from co-contributing to Tfh cell migration and
germinal center localization, sustained high expression of ICOS is also necessary for Tfh cells to
remain localized to B cell follicles [26]. Signaling through the ICOS receptor “overrides” the
strong PD-1 signaling that is simultaneously occurring in Tfh cells, as evidenced by the PD-1
mediated inhibition of Tfh cell recruitment into B cells follicles that was only overcome through
consistent and strong ICOS signaling [27]. PD-1 signaling in Tfh cells via its ligand PD-L1,
which is present on both cognate and bystander B cells, provides strong inhibitory signals to Tfh
cells by recruiting cytoplasmic phosphatases that dephosphorylate key T cell activation
molecules downstream of the TCR such as the CD3 epsilon chain, ZAP-70, and PKC, as well as
reduce PI3K-associated activities downstream of CXCR5, ICOS, and CD28 [27,146–148]. In
this way, the expression of PD-1 signaling Tfh cells is a form of negative selection, ensuring that
only Tfh cells that express high quantities of ICOS and CXCR5 remain active and localized to the
B cell follicles [27]. As ICOS signaling promotes the expression of key Tfh cell molecules that
are involved in germinal center activities, such as CD40L, IL-21 and IL-4 [28,29], as well as the
maintenance of the Tfh cell phenotype, this PD-1-mediated selection for ICOS high expressing
Tfh cells (i.e., the Tfh cells with the greatest effector function capacity) is particularly important.
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Regarding Tfh cell molecules that specifically facilitate T cell-dependent humoral
responses in B cells, one of the most significant co-stimulatory signals provided to B cells is the
ligation of CD40L (CD154) on Tfh cells, whose expression is increased via ICOS signaling, with
CD40 on B cells. This interaction is crucial as it promotes affinity maturation by inducing
somatic hypermutation. The marked ICOS-mediated upregulation of IL-21 and IL-4 secretion by
Tfh cells is also important for providing proliferation and differentiation signals to nearby B cells
[21,22], with IL-21 in particular also providing autocrine signals to support the continued
expression of key Tfh cell-surface signaling molecules needed for GC localization and and
effector function[33]. Finally, PD-1 expression on Tfh cells, aside from selecting for ICOS high
expressing Tfh cells, is also thought to contribute to T cell-dependent humoral responses by
setting a threshold for the B cell competition that ultimately leads to affinity maturation [27,149].
Due to the previously mentioned PD-1-mediated suppression of TCR signaling, the ligand
sensitivity of Tfh cells is therefore also reduced [146,150]. This reduced sensitivity ensures that
the higher affinity B cells – which will bind, internalize, and therefore present more antigen to
Tfh cells than lower affinity B cells – receive “help” from Tfh cells [23,149,151,152]. B cells that
are deficient in PD-L1, thereby stimulating less PD-1 receptors on Tfh cells, received more help
from Tfh cells and result in the production of plasma cells with lower affinities [149].
Berberine
Berberine (BBR) is a plant-derived isoquinoline alkaloid found in the roots, rhizomes and
stem bark of plants within a variety of genera, such as Berberis (its namesake), Mahonia,
Hydrastis, and Coptis, among others. The full breadth of botanical sources, as well as the variety
of extraction methods, are well-described in a recent review by Neag et al. (2018) [57].
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Berberine has already proved to be of importance for a variety of diseases through
successful clinical trials, such as polycystic ovary syndrome [66,67], type II diabetes [68,69],
diarrhea-predominant irritable bowel syndrome [70], psoriasis [71], and osteoarthritis [72].
Additionally, BBR has been shown to successfully and strongly regulate the inflammatory
responses involved in clinically apparent autoimmune diseases in vivo such as collagen-induced
arthritis [75–78], type I diabetes mellitus [79], UC [80,81], and experimental autoimmune
encephalomyelitis [82].
Berberine has demonstrated the ability to inhibit the production of a variety of proinflammatory cytokines by various immune cells [83,84], having a strong anti-inflammatory
effect. Regarding CD4+ Th cell suppression specifically, BBR has been shown to act in vitro and
in vivo through a number of suggested mechanisms that ultimately inhibit the phosphorylation of
key signaling molecules and/or transcription factors that regulate the expression of genes
involved in activation, differentiation proliferation, and immune responses. Berberine-mediated
suppression of JAK/STAT phosphorylation has repeatedly been implicated in the inhibition of
Th1 differentiation [85–87] and Th17 differentiation [78,85–87]. One study in particular linked
this inhibitory effect of JAK/STAT signaling to the BBR-induced phosphorylation and activation
of AMPK [87]. The suppression of various MAPK signaling pathways, such as p38 MAPK
[86,88], ERK [77,88], and JNK [77,86,88] have also been observed.
Research Objective
Despite BBR’s observed role in vitro, in vivo, and in select clinical trials as an
immunosuppressant, as well as previous studies providing a role for BBR in regulating Th1,
Th17, and Treg activity, the effect of BBR on Tfh cells specifically has yet to be described. Thus,
we will be further examining the immunosuppressive role of BBR by evaluating its direct effect
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on Tfh cell differentiation and proliferation in vitro, as well as the expression of key cell surface
molecules involved in Tfh cell function. Further exploring BBR’s role as an inhibitor of Tfh cell
differentiation, proliferation and expression of molecules involved in Tfh cell effector function
will provide valuable insight into a novel function of BBR that is currently lacking in the
literature. First, this information will shed light on BBR’s role in collagen induced arthritis
suppression (a murine model of rheumatoid arthritis) that was observed in our previous research
[95]. Second, since Tfh cell and B cell interactions are so crucial to adaptive immune function,
specifically humoral immunity, the suppression of Tfh cell activity may have implications for the
general safety of BBR as a dietary supplement, and/or its potential use in antibody-driven
autoimmune and hypersensitivity disorders.
Methods
Assessment of T Cell CXC-Motif
Receptor 5 (CXCR5) Expression
in a Model of Humoral Immune
Response with a Berberine
Intervention
BBR was previously administered as a prophylactic treatment during induction of
arthritis in a CIA model. CIA is a suitable model to examine Tfh cell development, as it reliably
induces IgG class switching and production of specific anti-collagen type II (CII) autoantibodies,
indicating that Tfh-mediated B cell help is occurring. While we already observed significantly
reduced populations of Tfh cells and anti-CII IgG in the initial data analysis of our preliminary
research [95], we did not examine the expression of key cell surface molecule CXCR5 on Tfh
cells. Thus, we have revisited these data to also examine CXCR5 expression on Tfh cell
populations in order to further investigate the method by which BBR led to reduced anti-CII IgG
autoantibody production. A detailed description of all methods for CIA induction, assessment,
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and previous data analysis can be found in Vita et al. 2021 [95]. Briefly, CIA induction was
carried out using a protocol provided by Hooke Laboratories [153], with intraperitoneal BBR
administration (1 mg/kg/day) occurring daily from day 0 until day 28. CD4+ T cells from the
spleen and lymph nodes of BBR-treated mice, PBS (vehicle control) mice, CIA (CIA induction,
no treatment) mice, and control mice were collected at day 14 (n=5; pre-clinical phase model)
and day 28 (n=10). Single cell suspensions of splenocytes and lymph node (LN) cells were then
stained with fluorescent antibodies for CD4, CD3, and CXCR5. Expression of CXCR5 was
assessed by measuring the mean fluorescence intensity (MFI) of CXCR5 on CD3+CD4+ T cells
following flow cytometric analysis.
General Reagents for In Vitro Cell
Culture and Treatment Protocols
DMSO (VWR, Radnor, PA, USA), 1X PBS, berberine hydrochloride (Sigma-Aldrich, St.
Louis, MO, USA), ACK lysis buffer (Quality Biological, Gaithersburg, MD), RPMI 1640
supplemented to 2 mM L-glutamine, 1% v/v penicillin/streptomycin, 1 mM sodium pyruvate, 10
mM HEPES (all from ThermoFisher, Waltham, MA, USA), 0.05 mM β-mercaptoethanol (BioRad, Hercules, CA, USA), and 10% fetal bovine serum (VWR/Seradigm, Radnor, PA, USA), IL6 (Biolegend), anti-IL4 (BioLegend), anti-IFN-γ (BioLegend), UltraLeaf anti-CD28
(BioLegend), UltraLeaf anti-CD3 (BioLegend).
Fluorescent Antibodies
Fluorescent antibodies were used for flow cytometric analysis and fluorescent cell
sorting, and include APC anti-mouse CD4, APC/Cy7 anti-mouse CD3ε, Pacific Blue anti-mouse
CD19, FITC anti-mouse CXCR5, Pacific Blue ant-mouse ICOS, PE anti-mouse PD-1, and
recommended isotype controls (all from BioLegend, San Diego, CA, USA), and Propidium
Iodide Ready Flow (Thermo Fisher).
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Isolation of Naïve CD4+ T Cells
Via Fluorescent Cell Sorting
Spleens were harvested from C57BL/6 mice (male, 6-8 weeks old) in accordance with
IACUC protocol 2005C-NP-M-23 (Supplemental Figure 3.1 in Appendix B). Single cell
suspensions were then made from the spleens of euthanized mice. To create single cell
suspensions, briefly, spleens were ground, washed with 3 mL of ACK lysis buffer for 5 min, and
then strained into 35 mL of complete RPMI 1640. The resulting mixed splenocytes were then
stained with fluorescent antibodies specific for CD4 (APC), CD14 (PE), and CXCR5 (FITC). To
obtain a purified population of CD4+ T cells, the stained mixed splenocytes were sorted on using
a SONY SH800 by first sorting CD4+CD14+ monocytic cells out of the total CD4+ population;
the remaining CD4+CD14- were then sorted as CXCR5-. The resulting CD4+CD14-CXCR5population was expected to be naïve CD4+ T cells and confirmed via flow cytometry (>97%
pure; see Supplemental Figure 3.2 in Appendix B).
Pre-T Follicular Helper Cell Activation
and Differentiation In Vitro
As this differentiation protocol mirrored the initial interaction between naive CD4+ T
cells and DCs, the resulting differentiated Tfh cell population had “pre-Tfh cell-like” qualities, as
they would not become fully functional germinal center Tfh cell unless co-cultured with cognate
B cells. Cells were sorted by FACS as described above, and the purified naive CD4+ Th cells
were then differentiated in a protocol adapted from Andris et al. (2017) [49]. Briefly, CD4+ Th
cells (5x105 cell/ml) were seeded into a 24-well plate pre-coated with anti-CD3 (5 µg/ml) and
were incubated for 4 days in the presence of soluble anti-CD28 (2.5 µg/ml), IL-6 (20 ng/ml),
anti-IL4 (10 µg/ml) and anti-IFN monoclonal antibodies (10 µg/ml). Cells receiving
experimental treatment were exposed to either 0.25 µM, 0.5 µM, and 1.0 µM BBR or a volume-
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matched vehicle control (PBS and <0.01% DMSO) at the beginning of the 4-day incubation
period.
Flow Cytometry Data Collection Following
Pre-T Follicular Helper Cell Activation
and Differentiation In Vitro
Following the Tfh cell differentiation protocol and incubation period, the resulting cell
populations were stained with fluorescent antibodies specific for: CD3+CD4+ T helper (Th) cells,
CD3+CD4+CXCR5+ T follicular helper (Tfh) cells, as well as the cell-surface molecules ICOS
and PD-1 on CD3+CD4+CXCR5+ T follicular helper (Tfh) cells. Expression of cell surface
molecules was determined by measuring the MFI and the population data were determined by
measuring the percent positive cells. Example gating strategies can be found in Supplemental
Figure 3.3 in Appendix B.
Interleukin-21 Enzyme Linked
Immunosorbent Assay
(ELISA)
Following the Tfh cell differentiation protocol and incubation period, the cell supernatant
was collected for the measurement of IL-21 concentrations via ELISA as per the manufacturer’s
instructions and using manufacturer’s pre-made detection reagents (PeproTech). Briefly, plates
were coated with capture antibody and incubated at room temperature for 24 hours. Plates were
then washed in ELISA wash buffer, coated with blocking buffer, and incubated for 1 hour at
room temperature. Plates were washed again in ELISA wash buffer and incubated at room
temperature for 2 hours with the IL-21 standard serial dilutions and samples, followed by a wash
and incubation at room temperature for 2 hours with detection (secondary) antibody, then
followed by a wash and incubation with HRP-avidin conjugate for 30 minutes. Finally, plates
were then washed, and the ABTS development substrate was added to wells. Plates were
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monitored every 5 minutes for color change, and optical densities were taken at 450 nm using a
microplate reader.
Berberine Concentration-Response
Experiments
The final BBR concentrations used – 0.25 M, 0.5 M, and 1.0 M – were chosen based
on previously established in vitro work [24,39,50], and our own calculations based on average
oral bioavailability (<1%) [51] so the in vitro exposure of cells to BBR more accurately reflects
in vivo exposure. Cell viability of splenic T cells was measured following activation with
CD3/CD28 for 72-hours in the presence or absence of BBR. Cell viability was then measured
via flow cytometry using Propidium Iodide (necrotic cell detection) and Annexin V (apoptotic
cell detection) fluorescent staining. The BBR concentrations 0.25 µM and 0.5 µM did not lead to
any significant apoptotic or necrotic events (see Supplemental Figure 3.4 in Appendix B and
Figure 3.1 in Results).
Final Berberine Solutions
Used In Vitro
A stock solution of 10 mM berberine dissolved in DMSO was stored at −20 o C when not
in use. This stock solution was diluted in PBS to achieve the concentrations of 0.25 µM, 0.5 µM,
and 1.0 µM to be used in treatment protocols. All final DMSO concentrations were <0.01%.
Statistical Analysis
The assumption of normality was met for both cell population data and mean cell-surface
molecule expression data. Thus, for all comparisons the ANOVA test with Tukey’s multiple
comparisons test was used. All tests had an  = 0.05. All analyses were performed using Prism
version 8 (GraphPad, San Diego, CA, USA).

61
Results
Berberine Reduces T Cell CXCR5
Expression in a Model of Humoral
Immune Response with a
Berberine Intervention
In our previous study, BBR was administered as a prophylactic therapy during the
induction of arthritis in a CIA model [95]. CIA is a suitable model to examine Tfh cell
development, as it reliably induces IgG class switching and production of specific anti-collagen
type II (CII) autoantibodies, indicating that Tfh-mediated B cell help is occurring. While we
already observed significantly reduced populations of Tfh cells and anti-CII IgG in the initial data
analysis of our preliminary research [95], we did not examine the expression of key cell surface
molecule CXCR5 on Tfh cells.
Upon revisiting these data to examine CXCR5 expression on Tfh cell populations, we
determined that BBR did significantly reduce the expression of CXCR5 on CD3+CD4+CXCR5+
Tfh cells at the day 14 endpoint (pre-clinical endpoint) in the spleen and lymph nodes, with a
non-significant trend in reduction seen at the final day 28 endpoint (Figure 3.1). Additionally,
when comparing CXCR5 expression on Tfh cells within the spleen and lymph nodes at day 28 of
BBR-treated mice who developed arthritis versus BBR-treated mice that did not develop
arthritis, it was seen that Tfh cells in arthritic animals has significantly higher expression of
CXCR5 when compared to non-arthritic animals.
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Figure 3.1. Expression of CXCR5 on T follicular helper cells during pre-clinical collageninduced arthritis (day 14) and at final day 28 endpoints. Cells compared were from the
CD3+CD4+CXCR5+ T cell populations of LN and spleen, as these cells were considered to be Tfh
cells. Shown here is the expression of CXCR5 on CD3+CD4+CXCR5+ T cell populations of the
spleen (A) and lymph node (B) at the day 14 endpoint (n = 5 per group), and at the day 28
experimental endpoint (n = 10 per group). Additionally, shown is the expression of CXCR5 on
Tfh cells of the spleen (A) and lymph node (B) of BBR-treated mice who developed arthritis
(“arthritic”) versus BBR-treated mice who did not develop arthritis (“non-arthritic”). Statistical
analysis of CXCR5 made with ANOVA and Tukey’s multiple comparisons tests (* p < 0.05; **
p < 0.01).
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Impact of Varying Concentrations
of Berberine on Cell Viability
To assess the impact on BBR on cell viability, the percent of apoptotic and necrotic cells
was measured following BBR treatment. The use of BBR at 0.25 and 0.5 M did not
significantly contribute to necrotic or apoptotic events (Figure 3.2). In contract, the use of BBR
at 1 mM led to, on average, about a 10% increase in apoptotic events and about a 1.5 % increase
in necrotic events (Figure 3.2).

A

+

Apoptotic CD4 T cells

B

+

Necrotic CD4 T cells

Figure 3.2. The impact of BBR on cell viability. CD4+ T cells were activated in the
presence/absence of berberine (BBR; 0.25 M, 0.5 M, 1.0 M) for 72-hours. Apoptotic cells
(A) were measured as CD3+CD4+ T cells that were also positive for Annexin V staining (n = 6
per group). Necrotic cells (B) were measured as CD3+CD4+ T cells that were positive for
propidium iodide (PI) staining (n = 6 per group). Statistical analysis was made with ANOVA and
Tukey’s multiple comparisons tests (****p<0.0001).
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Berberine Inhibits the Differentiation
and Activation of Pre-T Follicular
Helper Cells In Vitro
To determine if BBR has a direct suppressive effect on Tfh cells, the population of
CD3+CD4+CXCR5+ Tfh cells (“pre-Tfh cells”) within the total CD3+CD4+ T cell population was
measured following activation and differentiation of pre-Tfh cells in the presence or absence of
BBR (0.0 M, 0.25 M  0.5 M, and 1.0 M), or a volume-matched vehicle control. BBR
treatment at 0.25 M, 0.5 M, and 1.0 M significantly reduced the population of pre-Tfh cells
within the total CD3+CD4+ T cell population (Figure 3.3). When the resulting percent positive
pre-Tfh cells of BBR-treated cells was compared with that of the volume-matched PBS vehicle
control, it was confirmed that the vehicle of BBR delivery did not impact the percent positive
pre-Tfh cells.

PBS control (volume-matched)
Berberine (BBR mM)
treatment data

Figure 3.3. Population of CD3+CD4+CXCR5+ pre-Tfh cells following activation and
differentiation in the presence or absence of berberine. Shown here is the percent of
CD3+CD4+CXCR5+ T cells within the total CD3+CD4+ T cell population following activation
and differentiation in the presence or absence of berberine (BBR; 0.25 M, 0.5 M, 1.0 M), or
a volume matched PBS vehicle control (n = 8 per group). Statistical analysis was made with
ANOVA and Tukey’s multiple comparisons tests (*p<0.05; **p<0.01, ***p<0.001,
****p<0.0001).
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Berberine Reduces Expression of Key
Cell Surface Molecules on Pre-T
Follicular Helper Cells During
Activation In Vitro
To further characterize the BBR-mediated suppression of Tfh cells, the expression of key
cell surface molecules CXCR5, ICOS, and PD-1 was examined on CD3+CD4+CXCR5+ Tfh cells
(“pre-Tfh cells”) following activation and differentiation of pre-Tfh cells in the presence or
absence of BBR (0.0 M, 0.25 M  0.5 M, and 1.0 M), or a volume-matched vehicle control.
At all concentrations, BBR treatment significantly reduced expression of CXCR5 and ICOS (see
Figure 3.4A). However, there was no apparent impact on PD-1 expression except for a nonsignificant trend of increased expression at 1.0 M. When the expression of CXCR5 and ICOS
on BBR-treated cells was compared with that of the volume-matched PBS vehicle control, it was
confirmed that the vehicle of BBR delivery did not impact the expression of these molecules (see
Figure 3.4B).
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Figure 3.4. Expression of cell surface molecules on CD3+CD4+CXCR5+ pre-Tfh cells following
activation and differentiation in the presence or absence of berberine. Naïve CD4+ T cells were
isolated from mixed splenocytes and differentiated into a pre-Tfh cell phenotype in the presence
or absence of berberine (BBR; 0.25 M, 0.5 M, 1.0 M) (A), or a volume matched PBS vehicle
control (B) (n = 8 per group). Shown are expression of CXCR5, ICOS, and PD-1 on
CD3+CD4+CXCR5+ T cells as the fold change of mean fluorescence intensity (MFI). Statistical
analysis of cell surface molecule expression made with ANOVA and Tukey’s multiple
comparisons tests (*p<0.05; **p<0.01, ***p<0.001, ****p<0.0001).
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Berberine Reduces Interleukn-21
Production By Pre-Follicular
T Helper Cells In Vitro
As IL-21 production by Tfh cells, in both the pre- Tfh stage and GC Tfh, is an important
autocrine signal for Tfh cells as well as paracrine signal for nearby B cells, we chose to examine
if BBR influenced IL-21 production by pre-Tfh cells. We observed that 0.25 M, 0.5 M, and 1
M BBR significantly reduced the production of IL-21 during the activation and differentiation
of naïve CD4+ Th cells into pre- Tfh cells (Figure 3.5).

A

PBS control (volume-matched)
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Figure 3.4. IL-21 production by CD3+CD4+CXCR5+ pre-Tfh cells following activation and
differentiation in the presence or absence of berberine. Naïve CD4+ T cells were isolated from
mixed splenocytes and differentiated into a pre-Tfh cell phenotype in the presence or absence of
berberine (BBR; 0.25 M, 0.5 M, 1.0 M) (A), or a volume matched PBS vehicle control (B).
Change in concentration of IL-21 (pg/mL) in cell supernatant is shown as the fold change from
BBR 0 or volume-matched control (n = 6 per group). Statistical analysis of cell surface molecule
expression made with ANOVA and Tukey’s multiple comparisons tests (*p<0.05; **p<0.01,
***p<0.001, ****p<0.0001).
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Discussion
In summary, BBR had a direct suppressive effect on Tfh cells, as seen through the reduced
percentage of pre-Tfh cells within the total CD4+ T cell population (i.e., fewer CD4+ Th cells
differentiated into pre-Tfh cells) following activation and differentiation in the presence of BBR,
as well as the decreased the production of IL-21 and the expression of CXCR5 and ICOS, but not
PD-1, on pre-Tfh cells. These results support our previous research which revealed that BBR
delayed the onset of CIA and appeared to do so by suppressing CD4+ Th cell activity, specifically
Tfh cell activity and downstream autoantibody production [95]. Since germinal center reactions,
when dysregulated, can contribute to the pathology of antibody-mediated autoimmune disease
[154,155], this inhibition of Tfh cell activity suggests a possible therapeutic role for BBR.
Conversely, the importance of successful germinal center reactions in effectively responding to
infection and vaccination [154,156] highlights a potential concern that use of BBR could
interfere with these critical immune responses.
As multiple previous studies demonstrated that BBR inhibits the activation,
differentiation, and proliferation of other CD4+ Th cell effector phenotypes (e.g., Th1, Th17)
[85,86,157], and it is perhaps unsurprising that BBR would directly inhibit the differentiation and
proliferation of Tfh cells as well, and also unlikely that the altered Tfh cell phenotype we observed
was due to BBR mediated-skewing of differentiating Tfh cells into a different effector phenotype.
Due to the recurrent theme of BBR generally suppressing CD4+ Th lineage cells, we proposed
that BBR interferes with cell signaling pathway(s) that are ubiquitous to all CD4+ Th cell effector
phenotypes, possibly during the initial stage of activation and differentiation. One such pathway
that had not yet been evaluated in T cells specifically in regard to BBR treatment was the Ca2+calcineurin-NFAT pathway following TCR ligation, although BBR did inhibit this pathway in
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bone marrow-derived macrophages [91] and RAW264.7 macrophages [93]. This pathway is
critical for all CD4+ T cell activation following TCR ligation. In Tfh cells, for example, NFAT1,2
activity is required for maintenance of ICOS, PD-1, and CXCR5 expression [96], and therefore
continued commitment to the Tfh cell program and germinal center reactions.
Another key cell signaling pathway that BBR has been shown to inhibit in CD4+ Th
helper cells, which his known to impact the differentiation of CD4+ Th cells into specific effector
phenotypes, is JAK/STAT signaling. Specifically, BBR has been shown to inhibit the
phosphorylation of JAK1, JAK2, STAT1, AND STAT4 involved in Th1 differentiation [85–87]
and STAT3 in Th17 differentiation [78,85–87]. Furthermore, BBR is known to inhibit the
phosphorylation of various MAPK signaling pathway molecules (p38 [86,88]; ERK [77,88];
JNK [77,86,88]). As STAT3 plays an important role in the differentiation and maintenance of Tfh
cells in response to IL-6 and IL-21 signaling [24,158,159], it is possible that BBR may interfere
with the phosphorylation of STAT3 in newly differentiating Tfh cells as well.
STAT3 interference may also be a possible mechanism for the decreased CXCR5 and
ICOS expression and IL-21 production that was observed in our in vitro model. BBR has been
shown to downregulate the expression of classic CD4+ Th cell co-stimulatory molecules in
multiple CD4+ Th cell effector phenotypes, such as CD28 and CD154 (CD40L) [95]. Our results
add to this previously described role of BBR as an inhibitor of CD4+ Th cell co-stimulatory
molecule expression by showing that BBR also inhibits the expression of ICOS, a classic costimulatory molecule of Tfh cells, as well as the canonical Tfh cell marker and chemokine
receptor CXCR5. However, the downregulation CXCR5 and ICOS, but not PD-1, is slightly
confounding as many of cell signaling pathways that lead to the upregulation of CXCR5, ICOS
and PD-1 during differentiation of Tfh cells are shared. For example, there is much evidence that
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IL-6-mediated STAT3 signaling during Tfh cell differentiation induces expression of Bcl6, the
key transcription factor that promotes the Tfh cell lineage [160–162]. Il-6-mediated Bcl6
expression then indirectly promotes the expression of Tfh differentiation and effector genes by
repressing the repressors of genes encoding for CXCR5, ICOS, PD-1, and IL-21, among others
[160]. Once IL-21 is produced, it reinforces the Tfh lineage in much the same way as IL-6 – by
signaling through STAT3 and reinforcing Bcl6 expression and the subsequent Bcl6-mediated
indirect expression of key Tfh cell differentiation and effector proteins [163].
However, while STAT3-mediated Bcl6 expression leads to the subsequent promotion of
not only ICOS and CXCR5, but also PD-1, we question whether the dependance of ICOS and
CXCR5 expression on STAT3-mediated Bcl6 activity during the early stages of Tfh cell
differentiation is perhaps more important than that of PD-1. During initial CD4+ T cell activation
and differentiation of the pre-Tfh cell phenotype, signaling through the IL-6 receptor in mice is
largely responsible for the initial expression of ICOS, which then subsequently contributes to the
expression of CXCR5 [25]. While IL-6-mediated STAT3 signaling can certainly enhance the
expression of PD-1, the fact that PD-1 expression is upregulated on all CD4+ Th cells following
activation in order to negatively regulate T cell expansion [164] indicates that its general
expression might be more dependent on a pathway that is utilized in the activation of all CD4+ Th
effector cell lineages following TCR ligation, such as the Ca2+-calcineurin-NFAT pathway.
Indeed, NFAT1,2 co-expression has been implicated as a requirement for optimal PD-1
expression following TCR ligation [96]. Additionally, while JAK/STAT signaling in general is
ubiquitous to all CD4+ Th cell effector phenotypes, signaling through different cytokine receptors
utilizes specific JAKs and STATs [159], and so the phosphorylation of the specific types of JAK
and STAT molecules themselves are largely dependent on the extracellular cytokine
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microenvironment. This variability is one of the multiple factors that contributes to the
differentiation of naïve CD4+ Th cell into different effector phenotypes [159], and so perhaps it is
important that PD-1, which is a classic T cell negative regulator (also known as a “checkpoint”),
be upregulated during T cell activation regardless of the extracellular cytokine milieu. As a
follow up to this current study, we will investigate if BBR impacts the phosphorylation of key
cell signaling molecules in the Ca2+-calcineurin-NFAT pathway following TCR ligation, and
STAT3 following IL-6 signaling, in an attempt to parse out exactly why BBR might be
downregulating CXCR5 and ICOS, but not PD-1, in newly differentiating pre-Tfh cells, as well
as the mechanism behind the BBR-mediated decrease in IL-21 production by pre-Tfh cells. It is
important to note, however, that while a disruption in STAT3 signaling could provide a possible
mechanism for the decrease in IL-21 production and CXCR5 and ICOS expression, especially at
the 0.25  and 0.5  concentrations of BBR for which cell viability matches that of untreated
cells (Supplemental Figure 3.4 in Appendix B) the suppression seen at 1 M is likely in part due
to some cell death.
While the analysis of these data show that BBR has an inhibitory effect on Tfh cells in
vitro and in vivo, our previous research examining BBR’s ability to delay the onset of CIA [95]
demonstrates that, in an animal model of antibody-mediated autoimmune disease, BBR treatment
only dampens germinal center activity and did not completely abrogate it. These findings may
have important implications for the use of BBR as a complementary immunosuppressive
therapy, as well as for individuals who are taking BBR for non-inflammatory pathologies (i.e.,
management of lipid and/or glucose metabolism). Thus, going forward, it is important to build
on these results and further characterize exactly how BBR may be interfering with the
differentiation of Tfh cells (i.e., mechanism) and the specific impact this might have on germinal
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center responses beyond just antibody production, such as the development of memory B cells
following infection or vaccination.
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Abstract
T follicular helper cells (Tfh cells) are a specialized subset of CD4+ T helper (Th) cells
that reside within secondary lymphoid organs and are typically characterized as
CXCR5+ICOS+PD-1+ cells. Our previous research revealed a novel function of berberine (BBR),
a clinically relevant herbal supplement, as a suppressor of Tfh cell differentiation, CXCR5 and
ICOS expression, and IL-21 production by pre-Tfh cells. However, it is unknown exactly how
BBR treatment inhibits these cells. As such, in the current research we examined the impact of
BBR treatment on the activity of key intracellular signaling molecules involved in Tfh cell
activation and differentiation following TCR ligation and/or CD28 signaling (p-ZAP-70, p-Lck,
p-PLC1, NFATc1 and intracellular calcium concentrations), as well as IL-6 signaling (pSTAT3), in order to gain greater insight into BBR’s mechanism of action.
Introduction
T Follicular Helper Cells
T follicular helper cells (Tfh cells) are a specialized subset of CD4+ T helper (Th) cells
that reside within secondary lymphoid organs and are typically characterized as
CXCR5+ICOS+PD-1+ cells [20–22]. These cells play a critical role in humoral immunity and
immunological memory by facilitating that germinal center responses in secondary lymphoid
organs that ultimately result in B cell affinity maturation, isotype class switching, and the
differentiation of B cells into long-lived plasma cells and memory B cells [21].
Tfh cell differentiation can be influenced by many factors and is a multistep process that
occurs within secondary lymphoid tissues. Upon high affinity interaction with antigen presenting
dendritic cells and in the presence of the right cytokine milieu (IL-6 in mice or IL-6/IL-12 in
humans, low IL-2), naïve CD4+ Th cells first differentiate into a transitional or “pre”-Tfh cell
[22]. This pre-Tfh phenotype is marked by an upregulation of the transcription factor Bcl-6,
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which commits the cell to the Tfh cell lineage versus other Th effector cell phenotypes (e.g., Th1,
Th2, Th17…etc.), as well as expression of the cell surface molecules ICOS, CXCR5, and PD-1
[22,24] that are characteristic of Tfh cells. Signaling through the IL-6 receptor, which results in
the activation and nuclear translocation of STAT3, is largely responsible for the expression of
Bcl6 and the simultaneous repression of IL2R receptor expression, thus directing the
differentiating cell away from a Th1 fate and towards a Tfh fate [160,161,163]. The IL-6mediated expression of Bcl6 via STAT3 then indirectly promotes the upregulation of key Tfh cell
surface molecules CXCR5, ICOS, and PD-1, as well as IL-21 production, by repressing
transcriptional repressors of those genes [160].
ICOS acts as both a co-stimulatory molecule and cell migration facilitator; CXCR5 is a
key chemokine receptor that facilitates migration to the T-B border and eventually into the B cell
follicle, and PD-1 acts as a negative regulator and germinal center localizer [27,29,145,165].
These cell surface molecules, however, are not yet expressed in high quantities on these newly
differentiated “pre-Tfh” or transitional Tfh cells, a fact which is important to note as it
distinguishes the pre-Tfh cell phenotype from fully mature germinal center (GC) Tfh cells which
have a higher expression of each [22].
The Role of Nuclear Factor of Activated
T Cells in T Follicular Helper
Cell Activation
Along with CXCR5, ICOS, and PD-1, which are hallmarks of Tfh cell differentiation and
effector function, the Ca2+-calcineurin-NFAT pathway deserves special mention as it is a key
pathway that contributes to Tfh cell activation following TCR ligation [96]. Without initial
signaling through this pathway, none of the above-mentioned activities leading to Tfh cell
differentiation would occur.
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When the initial CD4/TCR:MHC class II interaction occurs during an immune response,
the intracellular signaling cascade that follows – which involves the subsequent phosphorylation
and activation of molecules such as ZAP-70/Syk, Lat, Lck, PLC1, and others– ultimately results
in the initiation of various intracellular processes key to Tfh cell activation and differentiation,
including Ca2+ release from the endoplasmic reticulum (ER; [166]). Simultaneous ligation of the
CD28 co-stimulatory receptor results in some intracellular signaling cascades which are unique
to that of CD4/TCR signaling (e.g., PI3k/Akt), while others are redundant and serve to amplify
those activated by CD4/TCR signaling (e.g., Lck, PLC1) (cite). It is widely known that
phosphorylated PLC1 hydrolyzes PIP2 into IP3 and DAG; whereas DAG leads to the increased
activity of transcription factors such as ERK and NF-κB, IP3 binds Ca2+ channels in the form of
IP3-receptors that are localized to the membrane of the endoplasmic reticulum. This release of
intracellular Ca2+ stores is crucial to Tfh cell activation, as it then activates calcineurin, a
phosphatase that dephosphorylates and subsequently activates the NFAT family of transcription
factors [166]. It is important to note, however, that this initial release of Ca2+ from the ER is
rapid and transient. The sustained elevated intracellular Ca2+ level that are necessary for NFAT
to remain localized in the nucleus is dependent on store operated Ca2+ entry (SOCE), a process
by which the depletion of intracellular Ca2+ triggers the increased formation of STIM1,2-gated
Ca2+ channels in the plasma membrane, leading to an influx of extracellular Ca2+ that replenishes
intracellular stores [166,167].
In regard to Tfh cell activation and differentiation specifically, studies suggest that both
NFAT1,2 activity are critical for expression of the key molecules previously mentioned as being
necessary for Tfh cell activity, such as CXCR5, ICOS and PD-1 [96], as well as IL-21 production
by Tfh cells [168]. Additionally, evidence indicates that the Ca2+-calcineurin-NFAT pathway is

77
enhanced in Tfh cells compared to other Th cell effector phenotypes [168,169], with increased
intracellular Ca2+ concentrations and NFAT nuclear translocation, suggesting that Tfh cell
dependance on this pathway perhaps surpasses that of other Th cells. The examination of these
cells in NFAT1,2 deficient mice in vivo further supports this hypothesis by demonstrating that
lack of NFAT1,2 resulted in a decrease in total frequency of CXCR5+ Tfh cells and increased
expression of KLRG1 in CD4+ Th cells, indicating that NFAT1,2-deficiency polarized these cells
away from Tfh phenotype and towards a Th1 phenotype [96]. NFAT2 in particular (also called
NFATc1)– is highly expressed in Tfh cells, and to a greater degree than NFAT1 [169].
Furthermore, the expression of key Tfh cell markers (ICOS and PD-1) and associated activities
were impacted more so by a deficiency in NFAT2 as opposed to NFAT1 [96].
Berberine and T Cell Suppression
Berberine (BBR) is a plant-derived isoquinoline alkaloid found in the roots, rhizomes and
stem bark of plants within a variety of genera, such as Berberis (its namesake), Mahonia,
Hydrastis, and Coptis, among others. BBR has demonstrated the ability to inhibit the production
of a variety of pro-inflammatory cytokines by various immune cells [83,84], having a strong
anti-inflammatory effect. Regarding CD4+ T cell suppression specifically, BBR has been shown
to act in vitro and in vivo through a number of suggested mechanisms that ultimately inhibit the
phosphorylation of key signaling molecules and/or transcription factors that regulate the
expression of genes involved in activation, differentiation proliferation, and immune responses.
BBR-mediated suppression of JAK/STAT phosphorylation (JAK1, JAK2, STAT1, AND
STAT4) has repeatedly been implicated in the inhibition of Th1 differentiation [85–87] and Th17
differentiation via STAT3 [78,85–87]. One study in particular linked this inhibitory effect of
JAK/STAT signaling to the BBR-induced phosphorylation and activation of AMPK [87]. The
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suppression of various MAPK signaling pathways, such as p38 MAPK [86,88], ERK [77,88],
and JNK [77,86,88] have also been observed, where BBR treatment resulted in decreased
phosphorylation of these molecules. Additionally, there is evidence that BBR activates the aryl
hydrocarbon receptor (AhR), which has been linked to the induction of FOXP3 and the T
regulatory (Treg) phenotype from naïve CD4+ T cells [89]. Finally, the activation of AMPK in
CD4+ T cells observed by Takahara et al (2019) [87] that led to decreased JAK/STAT
phosphorylation indirectly provides a possible mechanism of action for other pathways that can
be suppressed by AMPK activity for which BBR has also been shown to inhibit, such as NFB,
MAPK/JNK and ERK.
Furthermore, there are BBR-mediated suppressive mechanisms that have been
demonstrated only in non-T cell lines but whose signaling pathways also exist in CD4+ T cells
(e.g., Akt, Ca2+-calcineurin-NFAT, MAPK, NF-kB [88,90]), where BBR decreased the
phosphorylation of signaling molecules and expression of gene products, as outlined extensively
in a recent review by Wong et al (2019) [94]. In regards to BBRs regulation of the Ca2+calcineurin-NFAT pathway, which also plays a crucial role in Tfh cell activation, BBR inhibited
Ca2+-calcineurin-NFAT signaling in bone marrow derived macrophages (BMMs) [88,91] and
RAW264.7 macrophages [93]; In these cells, BBR attenuated RANKL-induced [88,91] and LPSinduced [88,93] osteoclastogenesis via inhibition of Ca2+-calcineurin-NFAT signaling pathway,
as seen through a decrease in Ca2+ cytosolic influx and reduced NFATc1 expression and activity.
In models involving LPS-induced osteoclastogenesis specifically, expression of other signaling
molecules upstream of Ca2+ release were also reduced, such as TLR4, TRAF6, and PLC1 [93].
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Research Objective
Despite BBR’s observed role in vitro, in vivo, and in select clinical trials as an
immunosuppressant, studies have yet to elucidate specific mechanism of action by which BBR is
exerting an inhibitory effect on Tfh cells. Thus, this research provides valuable insight into key
information that is currently lacking in the literature: A direct mechanism for the BBR-mediated
suppression of Tfh cells – including a possible mechanism for the inhibition of differentiation and
expression of CXCR5 and ICOS observed in our previous research. Here we investigated the
impact of BBR on the Ca2+-calcineurin-NFAT pathway following TCR ligation and STAT3
phosphorylation following IL-6 signaling, both of which have not been previously studied in the
context of Tfh cells.
Methods
General Reagents
DMSO (VWR, Radnor, PA, USA), 1X PBS, berberine hydrochloride (Sigma-Aldrich, St.
Louis, MO, USA), ACK lysis buffer (Quality Biological, Gaithersburg, MD), RPMI 1640
supplemented to 2 mM l-glutamine, 1% v/v penicillin/streptomycin, 1 mM sodium pyruvate, 10
mM HEPES (all from ThermoFisher, Waltham, MA, USA) 0.05 mM β-mercaptoethanol (BioRad, Hercules, CA, USA), and 10% fetal bovine serum (VWR/Seradigm, Radnor, PA, USA), IL6 (Biolegend, San Diego, CA, USA), anti-IL4 and anti-IFN-y (BioLegend, San Diego, CA,
USA), UltraLeaf anti-CD28 and UltraLeaf anti-CD3 (BioLegend, San Diego, CA, USA) Fluo-4AM Ester (BioLegend, San Diego, CA, USA), Calcimycin (source), Bovine serum albumin
(BSA;VWR), biotinylated anti-CD3 and biotinylated anti-CD28 (BioLegend, San Diego, CA,
USA), Streptavidin (Biolegend, San Diego, CA, USA).
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Fluorescent Antibodies
Fluorescent antibodies were used for flow cytometric analysis and fluorescent cell
sorting, and include APC anti-mouse CD4, APC/Cy7 anti-mouse CD3ε, PE anti-CD14, Pacific
Blue anti-mouse CD19, FITC anti-mouse CXCR5, PE anti-mouse phospho-ZAP70, PE antimouse phospho-Lck, PE anti-mouse phospho-PLC PE anti-mouse NFATc1, and
recommended isotype controls (all from BioLegend, San Diego, CA, USA).
Berberine Solutions
BBR concentrations used for final treatment were optimized as described in Data Chapter
3 and cell viability confirmed via flow cytometric analysis of apoptotic (Annexin V) and necrotic
(Propidium Iodide) CD4+ T cells (Supplemental Figure 3.4 in Appendix B). A stock solution of
10 mM berberine dissolved in DMSO was stored at −20 o C when not in use. This stock solution
was diluted in PBS to achieve the concentrations of 0.25 µM, 0.5 µM, and 1.0 µM to be used in
treatment protocols. All final DMSO concentrations were <0.01%.
Magnetic Cell Sorting Protocol
Spleens were harvested from C57BL/6 mice (male, 6-8 weeks old) in accordance with
IACUC protocol 2005C-NP-M-23 (Supplemental File 4.1). CD4+ T cells were then sorted out of
single cell suspensions of mixed splenocytes using a negative selection approach with the
MojoSort Magnetic Cell Separation System (Biolegend, San Diego, CA, USA), according to the
manufacturer’s instructions. Briefly, splenic single cell suspensions were strained, centrifuged at
250 g, and resuspended in 1X MojoSort Buffer (Biolegend, San Diego, CA, USA). Cells were
incubated for 15 minutes at room temperature with MojoSort mouse “untouched” CD4 T cell
biotin-antibody cocktail (Biolegend, San Diego, CA, USA), followed by a 15-minute room
temperature incubation with MojoSort SAV-nanobeads (Biolegend, San Diego, CA, USA). The
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antibody and nanobead-loaded cells were then incubated at room temperature inside the
MojoSort magnet for 10 minutes for cell sorting. Stromal, myeloid, and CD4- T cells are
captured by the antibody-conjugated beads and precipitated from suspension by incubation in the
magnet. Following incubation inside of the magnet, the supernatant containing uncaptured CD4+
T cells was collected and used for cell protocols. Purity of cells was confirmed via flow
cytometry to be >95% pure (Supplemental File 4.2).
T Cell Activation for Immediate Detection
of Intracellular Signaling Molecules
CD4+ T cells were seeded onto a 24-well plate and incubated at 37°C for 24 hours in
complete RPMI medium. During this 24-hour incubation period, cells receiving BBR treatment
were also incubated with either 0.25 M, 0.5 M, or 1.0 M BBR or volume-matched vehicle
control. Following incubation, cells were then transferred to a 24-well plate pre-coated with antiCD3ε and soluble anti-CD28 at 5 g/mL each in complete RPMI for T cell activation. The
activation reaction was stopped at either 5, 15, or 30 minutes by pipetting cells into 2 mL conical
vials on ice and then immediately centrifuging for 5 minutes at 250 g.
Pre-T Follicular Helper Cell Activation
and Early Differentiation
CD4+ T cells (5x105 cell/ml) were seeded into a 24-well plate pre-coated with anti-CD3ε
(5 µg/ml) and were incubated for 2 days in the presence of soluble anti-CD28 (2.5 µg/ml), IL-6
(20 ng/ml), anti-IL4 (10 µg/ml) and anti-IFN monoclonal antibodies (10 µg/ml). Cells receiving
experimental treatment were exposed to either 0.25 µM, 0.5 µM, and 1.0 µM BBR or a volumematched vehicle control (PBS and <0.01% DMSO) at the beginning of the 2-day incubation
period. The 2 day incubation period was chosen to capture pre-Tfh cells during the early stages of
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differentiation from CD4+ Th cells, as Tfh cells have been detected as early as 2 days after initial
activation in previous studies [24].
Flow Cytometry
For staining of intracellular signaling molecules, the supernatant of cell suspensions was
removed, and 500 mL of fixation buffer BioLegend, San Diego, CA, USA was added to the cell
pellet and incubated at room temperature in the dark for 20 minutes. A standard intracellular
antibody staining protocol for either PE anti-phospho-ZAP-70, anti-phospho-Lck, anti-phosphoPLC, anti-NFATc1, and anti-phospho-STAT3 (BioLegend, San Diego, CA, USA) using 1X
permeabilization buffer (BioLegend, San Diego, CA, USA). For any cells also being stained
extracellularly with APC anti-CD4 and FITC anti-CXCR5, a standard extracellular staining
protocol was followed prior to intracellular staining. Cells for all experiments were then analyzed
on an Attune NxT (ThermoFisher) flow cytometer as per the described gating strategies, which
can be found in the supplemental materials (Supplemental Files 4.3-4.5).
Calcium Mobilization and Detection
Assay Via Flow Cytometry
After the cell sorting protocol, cells were then seeded onto a 24-well plate and incubated
at 37°C for 24 hours in complete RPMI medium. During this 24-hour incubation period, cells
receiving BBR treatment were also incubated with either 0.25 M, 0.5 M, or 1.0 M BBR or
volume-matched vehicle control. Following incubation, cells were centrifuged for 5 minutes at
250 g and resuspended in calcium-free PBS supplemented with 0.5% of BSA for indicator
loading. Fluo-4 AM Ester (ThermoFisher) was added to wells at 1μM per 1 × 107 cells/mL for 45
minutes at 37°C. Cells were washed and resuspended in calcium free PBS supplemented with
0.5% of BSA and rested for 30 minutes at room temperature to allow for sufficient cleavage of
AM esters, rendering the Fluo-4-AM cell impermeable. Cells were then treated with 5 g/mL
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soluble biotinylated anti-CD3ε and 5 g/mL soluble biotinylated anti-CD28 (both from
BioLegend, San Diego, CA, USA) for 20 minutes at room temperature. The baseline
fluorescence of Fluo‐4‐AM (BL-1 channel) in CD4+ T was then acquired by flow cytometry on
an Attune NxT cytometer (ThermoFisher) for 60 seconds without stimulus. The sample tube was
briefly removed, and cells were stimulated with the addition of 20 g/ml streptavidin to induce
cross-linking of antibody bound CD3 and CD28 receptors. Stimulated samples were then
recorded for an additional 240 seconds to detect any increases in Fluo‐4‐AM fluorescence. The
sample tube was briefly removed, and cells were further stimulated with the addition of 1 μM
Calcimycin as a positive control. All data for calcium mobilization was taken from the peak
fluorescence values of a kinetics plot, gated as shown in Supplemental File 4.6.
Statistical Analysis
Shapiro-Wilk test confirmed that the assumption of normality was met for all samples.
An ANOVA was used to compare samples with an  = 0.05. All analyses were performed using
Prism version 8 (GraphPad, San Diego, CA, USA).
Results
The Effects of Berberine on Key Intracellular
Signaling Molecules During Early Pre-T
Follicular Helper Cell Differentiation
Intracellular concentrations of cytoplasmic NFATc1 and phosphorylated p-STAT3 were
measured following the activation and differentiation of CD4+ T cells into pre-Tfh cells in the
presence or absence of BBR (or a vehicle control); the cell culture occurred for 48 hours to
capture early pre-Tfh cell differentiation. BBR treatment significantly reduced the concentration
of p-STAT3 in early pre-Tfh cells (Figure 4.1A). However, BBR treatment did not significantly
impact cytoplasmic NFATc1 protein concentrations (Figure 4.1B).
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PBS control (volume-matched)
Berberine (BBR M) treatment

A
B

Figure 4.1. Concentration of key intracellular signaling molecules in CD3+CD4+CXCR5+ preTfh cells following activation and differentiation in the presence or absence of BBR. Naïve CD4+
T cells were isolated from mixed splenocytes and differentiated into a pre-Tfh cell phenotype in
the presence or absence of berberine (BBR; 0.25 M, 0.5 M, 1.0 M) (A), or a volume matched
PBS vehicle control (B) (n = 6 per group). Shown is the concentration of the phosphorylated
form of p-STAT3 and cytoplasmic NFATc1 following differentiation. The concentration is
represented as the fold change of mean fluorescence intensity (MFI). Statistical analysis of cell
surface molecule expression made with the ANOVA and Tukey’s multiple comparisons tests
(*p<0.05; **p<0.01, ***p<0.001, ****p<0.0001).

The Effects of Berberine on Key Intracellular
Signaling Molecules Immediately Following
T Cell Activation
Following pre-treatment with BBR for 24 hours, naïve CD4+ T cells were activated and
the concentrations of phosphorylated p-ZAP-70, p-PLCy1, and p-LCK were measured at 5minute, 15-minute, and 30-minute timepoints; total cytoplasmic concentration of NFATc1 was
also measured at these timepoints. Pre-treatment with BBR for 24 hours did not significantly
impact the concentration of p-PLCγ, p-ZAP-70, or p-Lck (Figure 4.2A-C) at any of the time
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points in activating CD4+ T cells. Pre-treatment with BBR also did not have an impact on the
cytoplasmic concentration of NFATc1 at any of the time-points (Figure 4.2D).

Figure 4.2. Concentration of key intracellular signaling molecules in CD3+CD4+ T cells at
select time points following activation. Naïve CD4+ T cells were isolated from mixed splenocytes
(n = 6 per group), pre-treated for 24 hours with BBR (0.25 M, 0.5 M, 1.0 M) and activated.
Shown are concentrations of the phosphorylated forms of key signaling molecules p-PLCγ1 (A),
p-ZAP-70 (B), and p-Lck (C), as well as cytoplasmic NFATc1 (D). The concentration is
represented as the fold change of mean fluorescence intensity (MFI). Statistical analysis of cell
surface molecule expression made with the ANOVA and Tukey’s multiple comparisons tests.
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The Effects of Berberine on Intracellular
Calcium Mobilization
Following pre-treatment with BBR for 24 hours, naïve CD4+ T cells were activated, and
intracellular calcium mobilization was measured. To quantitate mobilization, the peak value of
intracellular Ca2+ concentration was measured while cells were in an unstimulated state and then
subtracted from the peak value of stimulated (activated) cells. Calcimycin was used as a positive
control following cell activation. Pre-treatment of naïve CD4+ T cells with 0.25 M and 0.5 M
BBR elicited a significant reduction in intracellular Ca2+ concentration following T cell
activation, and pre-treatment with 1 M BBR elicited a significant decrease (Figure 4.3).

Figure 4.3. Calcium mobilization in CD4+ T cells following activation. Naïve CD4+ T cells were
isolated from mixed splenocytes and activated. Shown is the difference in the peak value of Ca2+
concentrations before and after stimulation (n = 6 per group), indicating the magnitude of Ca2+
mobilized after activation. The concentration is represented as the fold change from the BBR 0
group’s peak fluorescence values. Statistical analysis of cell surface molecule expression made
with ANOVA and Tukey’s multiple comparisons tests (*p<0.05; **p<0.01, ***p<0.001,
****p<0.0001).
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Discussion
Due to the importance of Tfh cell activity in humoral immunity and immunological
memory, and its role in antibody-mediated autoimmunity, the BBR-mediated suppression of Tfh
cell activity has important implications for both the use and safety of BBR as a dietary
supplement. As such, it is important to characterize exactly how BBR may be interfering with Tfh
cell activation and differentiation.
The suppressive effect of BBR on various CD4+ Th cell subsets is well documented,
especially regarding activation and differentiation, including our own previous study which
observed a BBR-mediated decrease in CD4+ Th cell expansion and reduced expression of costimulatory molecules CD28 and CD154 [95], and so we expected to see a downregulation in the
activity of key molecules downstream of the TCR and CD28 co-stimulatory receptor. However,
in this study, we observed that BBR did not impact the activity of cell signaling molecules pZAP-70, p-Lck, p-PLC1, and NFATc1 following CD3 and CD28 ligation at 5-, 15- and 30minutes post-activation. Although we did observe a significant decrease in Ca2+ release, the
maintained activity of NFATc1 indicates that the magnitude of this decrease is perhaps not great
enough to impact the function of NFATc1. This may, however, contribute to the BBR-mediated
decrease in IL-21 secretion by pre-Tfh cells that was observed in the Chapter III Results, as Ca2+
is required for vesicle exocytosis.
While we are not aware of any previous studies examining the impact of BBR on p-ZAP70 and p-Lck, there is evidence for the BBR-mediated suppression of PLC1 and NFATc1
activity in monocytic cell lines [88,93]. In those studies, BBR suppressed the activity of these
molecules when cells were stimulated with either LPS or RANKL. It is important to note,
however, that the cell lines and inflammatory stimuli used in these studies are different than our
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own. It is known that BBR competes with LPS for TLR4 binding [170], and so the lack of
PLC1 and NFATc1 suppression observed in our own study may be due to the different pathway
of cell activation (CD3/CD28). Thus, it is likely that BBR has different mechanisms of action in
T cells versus other cell lines, and in response to different stimuli, based on the molecule(s) BBR
is directly interacting with.
Due to BBR’s lack of impact on the above-mentioned molecules downstream of the TCR
and CD28 receptor, coupled with the observed decrease in phosphorylated STAT3 in pre-Tfh
cells, we propose that BBR is somehow interfering with cytokine receptor signaling and/or the
associated downstream signaling molecules. Previous studies highlight that BBR treatment led to
decreased JAK/STAT phosphorylation in Th1 and Th17 cells [86,94,157], and was associated
with reduced differentiation of those cells. As such, the inhibition of STAT3 phosphorylation
observed in BBR-treated cells within our study corroborates previous findings which
demonstrate a similar effect on STAT3 in Th17 cells [78,86], and provides further evidence for
the role of BBR as a suppressor of cytokine signaling within the CD4+ Th family of cells.
Additionally, this provides a possible mechanism for the decreased differentiation of pre-Tfh cells
from CD4+ Th cells described in Chapter III, along with the decreased expression of CXCR5 and
ICOS, and reduced IL-21 production by pre-Tfh cells. STAT3 is known to play role in the
differentiation and maintenance of Tfh cells in response to IL-6 and IL-21 signaling, as it directly
promotes the expression of Bcl6, subsequently leading to the upregulation of key Tfh molecules
such as CXCR5, ICOS, and PD-1 [160].
Thus, by examining signaling molecules that associate with the cytoplasmic tails of the
TCR (i.e., ZAP-70), of CD4 and CD28 (i.e., Lck), and of the primary signaling cascade
downstream of the TCR that is crucial for CD4+ Th cell activation (i.e., PLC1- Ca2+-calcineurin-
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NFAT), as well as STAT3 downstream of the IL-6 receptor, we have provided more insight into
exactly where in the “chain of command” BBR may be eliciting its effects in CD4+ Th cells. Our
observations support a hypothesis that BBR is not directly interfering with activation of the TCR
or CD28 receptors themselves, but perhaps interferes with cytokine receptor signaling and/or
associates with cytokine-related signaling molecules directly in the cytoplasm. However, the
ambiguity of exactly what BBR is binding in order to suppress the activity of these molecules
highlights the need for further studies which utilize techniques that can directly determine what
specific molecules BBR is directly binding to both on and inside of T cells, such as surface
plasmon resonance (SPR), or cryo-EM, or isothermal titration calorimetry.
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CHAPTER V
CONCLUSIONS AND RECOMMENDATIONS
Conclusions
The overarching aim of this research was to determine if BBR interferes directly with Tfh
cell activation and differentiation, and if so, investigate how it might be exerting those effects. To
achieve this we first examined the use of BBR as a prophylactic intervention in a mouse model
of collagen induced arthritis (CIA; animal model of rheumatoid arthritis). As CIA is antibodymediated autoimmune disease, it is a reliable model for observing the impact of BBR on Tfh – B
cell interactions, subsequent autoantibody production, and the resulting pathology.
In this CIA model, BBR delayed onset of disease, reduced production of autoantibodies,
and appeared to do so through suppressing CD4+ Th cell activity, including Tfh cells. In BBRtreated mice, the reduced population of CD4+ T cells had a decreased expression of the costimulatory molecule CD28, which is crucial for T cell activation, and CD154 (CD40L), which is
crucial for providing stimulatory signals to APCs, including B cells. Regarding Tfh cells
specifically, the total population of CXCR5+ Tfh cells was reduced in BBR-treated mice, as well
as the expression of the lineage marker and crucial chemokine receptor CXCR5 on Tfh cells.
CD19+ B cell populations in BBR-treated mice were reduced to a lesser degree than that of CD4+
T cells, and they did not experience any significant decrease in co-stimulatory molecule
expression, despite producing less autoantibodies than mice who did not receive a BBR
intervention. Thus, we hypothesize that BBR treatment suppressed CD4+ Th and specifically Tfh
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cell activity and the B cell helping capacity of these cells, thus providing less stable activation
signals to B cells during germinal center (GC) reactions.
Further supporting this hypothesis are the results from our in vitro studies, in which BBR
was administered to isolated CD4+ T cells during their activation and differentiation into pre-Tfh
cells. Not only did fewer CD4+ T cells differentiate into pre-Tfh cells, but the expression of
CXCR5 and ICOS, as well as IL-21 production by these cells, was reduced. As a consistently
elevated expression of CXCR5 and ICOS, as well as IL-21 production, is required for the
maintenance the Tfh cell lineage and effector function [22,25], it is likely BBR interferes with the
development of a functional Tfh phenotype that is sufficient to facilitate robust GC responses.
This claim is additionally supported by the marked reduction of phosphorylated STAT3 in BBRtreated cells, a transcription factor which plays a role in the differentiating cell’s response to Tfh
lineage-inducing cytokines [160,161,171].
Interestingly, while we observed a reduction in phosphorylated STAT3, we did not
observe a decrease in the active forms of key signaling molecules involved in T cell activation
following TCR and CD28 ligation – such as p-ZAP-70, p-Lck, p-PLCy1 or NFATc1. Thus, we
further hypothesize that BBRs suppression of CD4+ Th and Tfh cells is not mediated through
direct interference with the TCR or CD28 receptors, and is instead mediated through interference
with cytokine receptor signaling and/or their downstream signaling components.
There are two other key signaling molecules that BBR has been shown to interfere with
which, although not measured in our own research, deserve special mention as they may explain
some of our observed BBR-mediated T cell suppression: mechanistic target of rapamycin kinase
(mTOR) and AMP-activated protein kinase (AMPK). Although there is no specific evidence as
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of yet to indicate BBR directly binds to these molecules, it is clear that BBR treatment impacts
their activity [87,172–175].
The kinase mTOR, which includes distinct complexes mTORC1 and mTORC2, regulates
cell growth and metabolism by responding to diverse environmental signals such as available
nutrients, ATP levels, various mitogenic signals, and stressors, and ultimately acts to promote
glycolytic metabolism [176,177]. The kinase AMPK serves an opposite function and responds to
low intracellular ATP by inhibiting mTOR and promoting fatty acid oxidation [178]. In
proliferating cells, such as T cells and B cells undergoing clonal expansion following activation,
the promotion of glycolytic metabolism by mTOR provides quicker ATP production to fuel cell
division. Indeed, differentiation of naïve CD4+ T cells into Th1, Th2, and Th17 cells was
inhibited in mTOR-deficient cells in a TCR-independent manner [179,180]. In regard to Tfh cells
specifically, mTORC2 signaling appears to be essential for Tfh cell differentiation [181,182] and
mTORC1 in initial T cell proliferation [181], whereas strong consistent mTORC1 signaling via
IL-2 appears to inhibit Tfh cell differentiation [168].
BBR has been shown to upregulate the activity of AMPK in IL-17-producing CD4+ T
cells in a mouse model of inflammatory bowel disease, which was correlated to a decreased
frequency of those cells and hypothesized to be a contributing factor to the amelioration of the
disease [87]. Following a thorough search of online databases, we are led to believe that this is
the only peer reviewed article which describes BBR-mediated AMPK activation in T cells.
However, BBR-mediated AMPK activation has been repeatedly linked to its role as a modulator
of lipid and glucose metabolism in other cell types, contributing to protective effects against
dyslipidemia and hyperglycemia and thus having important implications for pathologies such as
type II diabetes, metabolic syndrome, cardiovascular disease, and others [174,175].
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Although it has yet to be explicitly described in regard to Tfh cells, and should certainly
be expanded upon in other CD4+ Th subsets as well, BBR-mediated activation of AMPK and
subsequent inhibition of mTOR could not only impact the phosphorylation of STAT3, but other
STATs downstream of different cytokine receptors. While STATs do not require interaction with
mTOR in order to become phosphorylated, there is significant cross-talk between these two
pathways, where mTOR signaling can enhance STAT activity and vice versa [183].
Additionally, in T follicular regulatory cells specifically, mTORC1 signaling was found to
promote STAT3 phosphorylation and subsequent Bcl6 expression [180]. Thus, our observation
that BBR reduced STAT3 phosphorylation could be due in part to a BBR-mediated AMPKdriven inhibition of mTOR.
Recommendations
Recommendation 1
As it stands, there are still three big gaps in the current research. First, many studies have
observed that BBR suppressed inflammatory responses by interfering with several signaling
cascades involved in the activation and effector function of various immune cells. These studies
are described in detail in the previous Manuscript Chapters II-IV. However, despite highlighting
that BBR impacts the phosphorylation and subsequent activity of numerous signaling molecules,
very few of these studies provide data as to whether BBR is directly binding to these molecules
to exert its inhibitory effect, or binding molecules further upstream. While previous work has
demonstrated BBRs ability to bind TLR4 [170] and RXR [184], and possibly weakly to AhR
[185], this may not wholly explain the BBR-mediated suppression of key signaling molecules
that are downstream of different receptors and/or inflammatory stimuli.
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TLR4, for example, is a pattern recognition receptor that binds LPS, a key component of
gram-negative bacterial outer membranes. While BBR has been shown to mediate cellular
responses to LPS stimulation [90,93,186], likely by binding antagonistically to TLR4 and thus
blocking the binding of LPS [170], there are many instances in which BBR has mediated the
immune responses of cells following other stimuli [77,94,95]. As such, the binding of BBR to
TLR4 alone does not explain many of the activities BBR has shown to elicit in T cells.
The binding of BBR to RXR however, may provide a better general mechanism for
some of the BBR-mediated suppression of T cell activation and differentiation in the presence of
different inflammatory stimuli although, again, does not seem to explain the “whole story.”
Vitamin A, also called retinoic acid, is the natural ligand of RXR, as well as RXRs and RARs
in general. Vitamin A and various RXR agonists have demonstrated the ability to reduce the
percentage of T lymphocytes in immunized mice [187], as well as specifically inhibit Th17
differentiation and promote the expansion of FOXP3 expressing iTreg [188–190]. However, there
is evidence that all-trans retinoic acid, a specific form of Vitamin A that binds both RARs and
RXRs, reduces the Th17 phenotype and promotes expression of FOXP3 in a STAT3 and STAT5
independent manner [188]. As such, the reduction in phosphorylated STAT3 observed in our
own research in response to BBR, a known RXR agonist, is likely mediated through another
mechanism. However, increased ratio of FOXP3+ Tregs: FOXP3- T effector cells observed in our
collagen induced arthritis mouse model [95] may be partially explained by BBR’s activity as an
RXR agonist.
While much work has demonstrated that BBR activates AhR, there is evidence that the
threshold for activation versus inhibition may be dose dependent [185]. Additionally, it remains
unclear if this occurs in a ligand-dependent or independent manner, with minimal evidence
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supporting that BBR may be a weak ligand [185] and other evidence supporting that BBR
mediates microbial activity which subsequently results in the formation of AhR ligands [191].
Regardless, this provides some insight into a possible mechanism behind the increased ratio of
FOXP3+ Tregs: FOXP3- T effector cells observed in our collagen induced arthritis mouse model
[95], as AhR activation is known to result in the expression of the FOXP3 transcription factor
and the formation of iTreg in the periphery [192]. Evidence regarding the role of AhR activation
in Tfh cells, however, is slightly less clear. We observed the BBR elicited significant suppressive
effects on Tfh cell proliferation and differentiation, yet there is recent evidence to suggest that
AhR activation would enhance Tfh cell proliferation and differentiation, not suppress it [193].
This impact of AhR activation on Tfh cells may be dependent on when and where AhR is
activated, however, as AhR activation during mouse development has been shown to result in a
reduced percentage of Tfh cells following influenza A virus infection later in life [194,195].
Moreover, based on the critical role of mTOR in initial T cell activation and
differentiation, coupled with mounting evidence that BBR modulates AMPK/mTOR activity, we
believe it critical for studies to be carried out which examine if BBR binds AMPK and mTOR in
CD4+ T cells, and further elucidate how BBR modulates the activity of these kinases in all CD4+
T cell effector phenotypes.
If any substance, whether it be an herbal supplement or more conventional
pharmaceuticals and immunotherapies, is going to be used to treat a serious pathology, it is
important to know exactly what the substance is interacting with and exactly how it is exerting
its effect. This has important implications for the targeted treatment of disease, as well as
potential drug interactions. Thus, we recommend that such studies be carried out (applicable
techniques include isothermal titration calorimetry, SPR, cryo-EM, etc.,) to build a clearer
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picture of how, where, and what extra- and intracellular components BBR is binding to, with a
priority on AMPK in CD4+ T cells.
Recommendation 2
Second, our research supports the hypothesis that BBR treatment suppresses Tfh cells in
such a way that it likely impacts the B cell helping capacity of these cells. However, to fully
assess if BBR-treated Tfh cell are truly providing less table activation signals to B cells during
GC interactions, anatomical studies of lymph nodes and/or spleens of mice treated with BBR
during an induced immune response (model of infectious disease, vaccine, etc.) should be carried
out. This would allow a deeper analysis of how BBR impacts GC development and subsequent
responses, which could have important implications not only for the management of antibodymediated autoimmune disease, but also for germinal center-derived adaptive immune responses
that play a kay role in response to infection or vaccination, and generating humoral
immunological memory.
Recommendation 3
Finally, there is widespread evidence that BBR has anti-inflammatory and
immunosuppressive capabilities, including our own data which supports the claim that BBR
interferes with Tfh cell development and suppresses GC activities. The current use of BBR as a
dietary supplement, however, often extends to uses that are unrelated to immune system activity.
For example, there are several clinical trials using BBR for the management of lipid and glucose
metabolism [74,196], and its impact on diseases such as type II diabetes [69] and polycystic
ovarian syndrome [67,197]. As such, these are among the more common reasons for which BBR
is used within the United States. Despite widespread evidence in vitro and in vivo, and in select
clinical trials, that BBR can suppress various inflammatory immune responses, there are no
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studies to date which examine how BBR is impacting immune function in individuals who are
taking BBR for non-immune-related issues. This raises the question: Are these individuals
potentially less effective at responding to a primary infection and/or at generating immunological
memory?
Our own results which demonstrate that BBR suppresses GC activity in an animal model
of antibody-mediated autoimmunity and directly inhibits Tfh cells, along with the multitude of
studies which show BBR inhibits the inflammatory responses of various CD4+ Th effector cell
lineages, macrophages, dendritic cells, and others [83], highlights the need for such an
examination.
Concluding Remarks
Taken together, these results provide additional insight into the mechanism of BBRmediated Tfh cell suppression, and support a hypothesis that BBR treatment suppresses CD4+ Th
and Tfh cell activity and the B cell helping capacity of these cells, thus providing less stable
activation signals to and germinal center interactions with B cells. In other words, BBR appears
to disrupt T cell-dependent humoral responses by having a direct suppressive effect on Tfh cells.
While this may be beneficial for the treatment of antibody-mediated autoimmune diseases, this
also raises concern that individuals taking BBR for non-immune related issues could have a
diminished germinal center response to primary infections and/or vaccinations.
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Supplementary Figure 2.1. IACUC approval letter. Shown is the IACUC approval letter for all
research carried out in Chapter 2.
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Supplementary Figure 2.2. Example of arthritic scoring. All animals were scored according to
instructions provided by Hooke Labs
(https://hookelabs.com/protocols/ciaInduction_DBA1.html). Score 0 = a normal paw; Score 1 =
one or two toes swollen, with no inflammation of paw or ankle; Score 2 = Three or more toes
inflamed and swollen, but no paw swelling, OR mild swelling of entire paw with no ankle
swelling; Score 3 = Swelling of entire paw, can include ankle swelling; Score 4 = Severe
swelling of entire paw and all toes, OR ankylosed paw and toes and the mouse cannot grip the
wire top of the cage.

128

Supplementary Figure 2.3. Gating strategy for T cell flow cytometry data. Depending on the
assay, the final CD3+CD4+ gate was then used as the parent gate for: a.) PE CD28 and APC
CD154 (depicted here); b.) APC CXCR5; c.) PE CD25 → Alexa Flour 647 FOXP3
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Supplementary Figure 2.4. Gating strategy for B cell flow cytometry data. Depending on the
assay, the final FITC CD19+ gate was then used as the parent gate for: a.) PE CD80 and APC
CD86 (depicted here) OR b.) PE CD40 and APC MHC II.
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Supplementary Figure 3.1. IACUC approval letter. Shown is the IACUC approval letter for all
research carried out in Chapter III. The approval letter is for Dr. Nicholas Pullen and covers the
use of mice for the described purposes by all graduate students enrolled in the Pullen Lab.
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Supplementary Figure 3.2. Purity of sorted naïve CD4+ T cells. Shown here is an example
gating strategy for checking the purity of sorted naïve CD4+ T cells following. Cells were sorted
on the SONY FACS as CD14-CXCR5-CD4+. First, the entire population was gated (Gate 1),
followed by the gating of singlets (Gate 2). Singlets were then analyzed to make sure that over
97% were CD4+ and CXCR5-.
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Supplementary Figure 3.3. Gating strategy for pre-Tfh cells. Shown here is an example gating
strategy for the identification of CD3+CD4+CXCR5+ T cells. First, possible debris was gated out
of the total events, followed by the exclusion of doublets. All singlets were then gated for
CD3+CD4+ T cells (C), which were then gated for CXCR5+ T cells within the CD3+CD4+ T cell
population. For all CXCR5 expression and CD3+CD4+CXCR5+ T cell population data, MFI and
percent positive cells were taken directly from the gating strategy ending in. For all ICOS
(Pacific Blue) and PD-1 (PE) expression data, the MFI was taken by separately gating for each
molecule off the CD3+CD4+CXCR5+ T cell population.
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Supplementary Figure 3.4. Impact of berberine on cell viability. Shown is the example gating
strategy for the determination of the percent of apoptotic (A) and necrotic (B) CD4+ T cells
following BBR treatment.
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Supplementary Figure 4.1. IACUC approval letter. Shown is the IACUC approval letter for all
research carried out in Chapter 4. The approval letter is for Dr. Nicholas Pullen and covers the
use of mice for the described purposes by all graduate students enrolled in the Pullen Lab.
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Supplementary Figure 4.2. Magnetic cell sort purity check and gating strategy for intracellular
targets. Shown is the initial gating strategy for the detection of intracellular targets in CD4+ T
cells following 24-hr BBR pre-treatment and cell activation. This same gating strategy was also
used to check the purity of the cell population after sorting CD4+ T cells from mixed
splenocytes.
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Supplementary Figure 4.3. Additional gating strategy for intracellular targets at various times
post-activation. All gates shown are derived from the original gating strategy shown in
Supplementary Figure 4.2.
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Supplementary Figure 4.4. Gating strategy for intracellular targets in pre-Tfh cells. Shown is
the gating strategy for the detection of p-STAT3 and NFATc1 in pre-Tfh cells.
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Supplementary Figure 4.5. Gating strategy for measurement of intracellular calcium
mobilization. Within the gates shown, peak fluorescence values were measured and used as a
proxy for peak concentration of calcium mobilization.

